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MECHANISMS PROMOTING ERK-DEPENDENT NEURONAL OXIDATIVE 
TOXICITY 
 
David Justin Levinthal, PhD 
 
University of Pittsburgh, 2004 
 
 
 
Glutamate-induced oxidative toxicity in HT22 cells and primary immature cortical 
cultures provides an excellent model system for studying oxidative stress-dependent 
neurodegeneration.  Glutamate treatment leads to cysteine and subsequent glutathione depletion, 
followed by the steady accumulation of reactive oxygen species (ROS).  This form of cell death 
depends upon the persistent activation, via phosphorylation, of extracellular signal regulated 
kinase (ERK) kinase-1/2 (ERK-1/2) that occurs during oxidative stress.  However the 
mechanisms responsible for this chronic activation of ERK during oxidative stress have not been 
well characterized.  In this thesis, I demonstrate that ERK activation is dependent upon the tonic 
activity of the phosphatidylinositol-3-kinase (PI3K)-Akt pathway and the subsequent activation 
of MEK.  Furthermore, the persistent ERK activation that leads to cellular toxicity can be driven 
by the oxidative-dependent inactivation of ERK-phosphatases.  Thus the balance of activating 
kinase activity and inactivating phosphatase activity dynamically regulates ERK-dependent 
signaling and is a major determinant of neuronal cell responses to oxidative stress.  The 
overexpression of a negative regulator of the ERK MAPK pathway, the ERK-specific 
phosphatase MKP3, led to protection of both HT22 cells and primary immature cortical cultures 
from oxidative toxicity.  Furthermore, a catalytically inactive form of MKP3 (MKP3 C293S) 
was shown to physically restrict activate ERK to the cytoplasm.  Because overexpression of 
MKP3 C293S was also shown to be neuroprotective, translocation of active ERK to the nucleus, 
 iii
but not ERK activation alone, must be required for glutamate-induced oxidative toxicity.  
Collectively, these results clearly place ERK activation as a necessary event that leads to 
neuronal cell death during oxidative stress and have revealed some unique mechanisms by which 
ROS accumulation drives ERK activation.  
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 2. INTRODUCTION 
2.1. Oxidative stress and neurodegenerative disease 
2.1.1. Physiological sources of ROS 
 
 Reactive oxygen species (ROS) are a family of oxygen containing molecules that include 
superoxide anion (O2-), hydroxyl radical (OH.), and hydrogen peroxide (H2O2).  Superoxide 
anions can interact with nitrogen containing molecules such as nitric oxide (NO.) to form 
peroxynitrite (ONOO-), a prototype member of the family of reactive nitrogen species (RNS).  
Collectively, ROS and RNS molecules vary in both their stability and ability to oxidize proteins, 
lipids, and nucleic acids in the cell, but the accumulation of these molecules in general is 
detrimental to normal cellular physiological function and often leads to cellular demise.     
  As the primary site of oxygen consumption in the cell, mitochondria represent an 
important source of intracellular ROS production.  Oxidative phosphorylation, the process by 
which energy is captured via the step-wise reduction of O2 to H2O, occurs in the mitochondria of 
eukaryotic cells.  Though by far most O2 becomes fully reduced to H2O during this process, 
partial reduction of oxygen leads to the formation of unstable oxygen radicals that quickly 
interact with molecular oxygen or water to form ROS.  Cells that have greater energy 
requirements and a higher metabolic rate, such as the cardiomyocytes found in cardiac tissue and 
the neurons within the nervous system, generally consume more oxygen and produce a greater 
amount ROS due to increased demands on mitochondrial oxidative phosphorylation.  Thus, these 
cells may be at increased risk for the accumulation of damaging ROS relative to most other cells 
in the body. 
 However, not all ROS production in the cell leads to cellular damage.  ROS production 
by NADPH oxidases and myeloperoxidases in discrete compartments within phagocytic 
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 neutrophils is part of an important host defense mechanism that allows for microbiocidal action 
in the phagolysosome.  Congenital defects in this system can have devastating compromising 
effects on immune function, underscoring the importance of ROS production to normal function 
(Cotran et al., 1999).  Furthermore, it is becoming clear that low levels of ROS can act as 
important signaling molecules in nearly all cells in the body via oxidation-dependent and 
reversible changes in cellular protein function.  The role of localized ROS production and 
participation in normal, physiological signaling events is an emerging field that is only beginning 
to be studied and understood.  The role of ROS in both normal and maladaptive signaling events 
will be discussed in more detail below. 
  
2.1.2.  ROS Defense Systems 
 
 To combat the deleterious effects of unnatural accumulation of ROS, several ROS 
defense systems have evolved to both passively and actively scavenge these molecules at 
different sites both within and outside of the cell.  Lipid-based scavengers of ROS are important 
pools of reducing agents that can quench both ROS and lipid peroxides that are themselves self-
propagating mediators of further oxidative damage.  These molecules include Coenzyme Q in the 
inner leaflet of the mitochondrial membrane and vitamin E in the plasma membrane.  Both CoQ 
and vitamin E have a passive mechanism of action by which electrons are transferred from ROS 
and lipid peroxides to sites on the molecule that are easily oxidized.  For CoQ, two electrons can 
be accepted in the formation of the stable, oxidized quinone form, while vitamin E can accept 
one electron in the formation of a resonance-stablized oxidized state.  Ascorbic acid (vitamin C), 
glutathione, and thioredoxin are major soluble ROS scavenging molecules that exist in the 
cytoplasm of the cell.  Ascorbic acid can accept two electrons in the conversion from the 
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 reduced, enol tautomeric form to the fully oxidized ketone form.  Interestingly, ascorbic acid is 
important for restoring vitamin E to its reduced form in vivo.  Glutathione and thioredoxin can 
specifically reverse the oxidation of thiol residues on proteins and collectively represent an 
important pool of soluble reducing agents.  Glutathione is a modified tripeptide (Glu-Cys-Gly) 
with the capacity to disrupt oxidized thiols on target proteins by direct nucleophilic reaction 
between the reduced cysteine of glutathione and the oxidized thiol in the target protein molecule.  
Thioredoxin is a ubiquitously expressed and highly conserved protein that utilizes two vicinal 
cysteine residues in its active site to transfer electrons from oxidized thiols / disulphides within 
target proteins (Holmgren, 1995).  While molecules such as CoQ, vitamin E, and vitamin C are 
important in preventing ROS accumulation, their action is necessarily stoichiometric and 
therefore can be easily overwhelmed by the presence of particularly high loads of ROS, oxidized 
lipids, and other oxidized molecules.  However, gluthathione and thioredoxin can be restored to 
their reduced forms by reductases, and this provides a mechanism by which these anti-oxidants 
can scavenge larger pools of ROS.     
 Several enzymatic systems with differing substrate specificities have evolved to actively 
quench and deactivate even larger pools of ROS.  The ubiquitous enzyme catalase, which 
specifically converts H2O2 to H2O and O2, is a prototype for this class of enzymes.  It is 
interesting to note that catalase has one of the most rapid rates of catalysis ever identified (Stryer, 
1995), further underscoring the importance of ROS scavenging and breakdown to the 
maintenance of normal cellular function.  Superoxide dismutase (SOD) has several isoforms that 
specifically convert superoxide radicals to hydrogen peroxide and molecular oxygen.  Within the 
cell, both manganese and copper/iron containing SOD isoforms function to scavenge superoxide 
radicals, while extracellular SOD functions in the connective tissue outside of the cell (Fattman 
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 et al., 2003).  Other ROS scavenging enzymes, such as thioredoxin- and glutathione-reductases, 
act indirectly by restoring the cellular pool of soluble scavengers to functional, reduced states.  
Examples of several ROS scavenging enzymatic and non-enzymatic reactions are shown in 
Figure 1 below. 
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Figure 1 Prototypical reactive oxygen species (ROS) scavenging enzym
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 2.1.3. Role of ROS in neurodegenerative diseases 
 
 The accumulation of ROS resulting from impairments in normal pro-oxidant / anti-
oxidant homeostasis, generally known as oxidative stress, has been implicated in the 
pathophysiology of a vast array of neurodegenerative disorders.  These diseases include stroke, 
Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis, among others, 
which collectively account for the most prevalent forms of neurodegenerative disorders in 
humans.  Furthermore, these diseases often involve the degeneration of specific subsets of 
neurons and do not appear to be general processes that affect the nervous system as a whole.  
Because most of these diseases occur over years or decades, yet oxidative stress can lead to 
neuronal demise in hours or days (e.g. during ischemia/reperfusion-induced neuronal 
degeneration), it is likely that these neurodegenerative disorders occur via the gradual, but 
selective, effect of a steady loss of neurons.  Eventually, disease symptoms are manifested when 
remaining neurons fail to compensate for this steady loss.  However, whether these disorders 
occur via a mechanism of gradual, selective loss of single neurons or a steady decline in 
functioning of all neurons within a specific neural system remains a subject of great debate.   
 The underlying cause of oxidative stress in chronic neurodegenerative disease is similarly 
controversial, and explanations ranging from purely environmental to purely genetic have been 
postulated.  While the literature investigating the link between oxidative stress and 
neurodegenerative disease is quite extensive and is beyond the scope of this discussion, several 
excellent reviews have been written on this topic (Simpson et al., 2003; Barnham et al., 2004; 
Milton, 2004).  However, highlighting a few examples of these links would be illustrative in 
underscoring the pivotal role of oxidative stress in neurodegeneration.  For example, idiopathic 
Parkinson's Disease (PD) has been associated with the exposure to certain pesticides that can 
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 inhibit specific enzymatic complexes that underlie oxidative phosphorylation in the mitochondria 
(Liou et al., 1997; Greenamyre and Hastings, 2004), while a familial form of the same disease 
can be manifested by mutations in the gene encoding the protein parkin (Kitada et al., 1998).  
Recently, deficits in complex I function have been demonstrated in leukocytes from Parkinson's 
patients with this parkin mutation, implying that parkin functions in part to regulate oxidative 
phosphorylation in mitochondria (Muftuoglu et al., 2004).  Complex I inhibition could be an 
important causal link between parkin mutations and the development of oxidative stress in the 
development of PD.  Most recently, mutations in the gene encoding the mitochondrial protein 
PTEN-induced kinase 1 (PINK1) have been associated with familial PD (Valente et al., 2004).  
This defect reveals yet another link between mitochondrial dysfunction and the development of 
PD.  Other familial forms of neurodegenerative disorders are also intimately linked with the 
regulation of ROS production.  For example, mutations in the Cu/Zn SOD1 isoform are 
associated with the development of the familial form of ALS (Rosen et al., 1993), and these 
mutations inhibit the dimerization of SOD1 necessary for full enzymatic activity (Deng et al., 
1993).  Furthermore, increased sensitivity to ROS/RNS may underlie the phenotype of familial 
forms of Parkinson's disease, which have been associated with mutations in the genes encoding 
the protein α-synuclein (Polymeropoulos et al., 1997).  Oxidation of α-synuclein is necessary for 
the dimerization and aggregation of the protein (Norris et al., 2003), and the two major α-
synuclein mutants, A30P and A53T, exhibit increased sensitivity to oxidation-dependent 
aggregation (Krishnan et al., 2003).    Thus critical mutations in specific genes may drive the 
development of neurodegenerative disorders either by direct impairment of oxidative 
phosphorylation and anti-oxidant systems or by increasing the sensitivity of proteins to the 
detrimental effects of ROS/RNS.  However, the familial forms of these neurodegenerative 
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 disorders represent the minority of cases.  Which mechanisms operate in any one affected 
individual is difficult to predict or determine, and it is likely that the sporadic forms of many of 
these diseases represent the cumulative effect of multiple maladaptive disruptions in several 
independent pathways.     
 The role of ROS in the pathology of acute neuronal injury, such as that seen during 
stroke, is well established.  Periods of ischemia followed by reperfusion can cause a robust 
increase in ROS in selective regions of the brain, such as the hippocampus, and lead to an 
apoptotic neuronal cell death that occurs over a short period of time (i.e. hours to days) (Kirino, 
1982; McCulloch and Dewar, 2001).  This form of delayed toxicity typifies the neuronal cell 
death that is observed in the penumbral region of tissue surrounding the ischemic, necrotic core 
(Kametsu et al., 2003).  Similarly, acute neuronal death due to potent neurotoxins can occur via 
the production of ROS.  For example, MDMA (also known as the street drug Esctasy) 
administration in mice induces striatal neuronal cell death that is dependent upon free radical 
formation in affected neurons (Camarero et al., 2002).  Furthermore, the household biocide, 
methylisothiozolinone, causes acute toxicity in cultures of cortical neurons via the cellular 
production of ROS (Du et al., 2002).   Thus, ROS production and neuronal toxicity are intimately 
linked across a range of neurodegenerative disorders both chronic and acute. 
      
2.2. Mitogen-activated protein kinases (MAPKs) 
 
2.2.1. MAPK members and general signaling pathway module 
 
 The mitogen-activated protein kinase (MAPK) family is involved in the signaling of 
numerous stimuli and stresses that impinge upon the cell and regulates such important cellular 
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 responses as adhesion, growth, proliferation, survival, and programmed cell death.  These 
molecules are highly conserved across a wide range of organisms – from yeast to humans – and 
play a key role in both normal physiology and disease.  MAPK members have traditionally been 
categorized into three primary divisions that include the extracellular signal-regulated kinase 
(ERK), the c-jun N-terminal kinases/stress activated protein kinase (JNK/SAPK), and the p38 
kinase families (Garrington and Johnson, 1999).  However, several new members of the MAPK 
family have been identified, such as ERK5 (Zhou et al., 1995) and ERK1b (Yung et al., 2000).   
 MAPKs operate within a canonical three-member signaling module that includes 
upstream MAPK kinases (MEKs or MKKs) and MEK/MKK kinases (MKKKs) (Robinson and 
Cobb, 1997).  Signals from nearly every ligand/receptor interaction are transduced via the 
activation of some MAPK cascade module, and the mechanisms by which receptors and various 
cellular stressors are linked to this activation have been the focus of innumerable studies.  In 
brief, both tyrosine kinase and G-coupled receptor activation can lead to the recruitment of the 
small GTPase, Ras, which can in turn drive the activation of the ERK signaling module through 
Ras-dependent activation of the various MKKK isoforms Raf1, A-Raf, and B-Raf (Robinson and 
Cobb, 1997).        
 All MAPK members are activated by dual-phosphorylation on a conserved activation 
loop on both a theonine and a tyrosine residue of the sequence T-X-Y (Bellon et al., 1999).  
Phosphorylation at both sites induces a conformational shift in the protein that leads to enzymatic 
activation, while removal of either phosphate or both leads to enzymatic inactivation 
(Canagarajah et al., 1997).  MAPKs themselves are effector kinases directed toward serine and 
threonine residues on target proteins both in the cytoplasm and in the nucleus.  Many of these 
targets are kinases themselves, and are generally referred to as MAPK-activated protein kinases 
9 
 or MAPKAPKs.  ERK1 (44 kDa) and ERK2 (42 kDa) are two closely associated isoforms of 
ERK that appear to be regulated in parallel in most systems.  Functional distinctions between the 
two have been difficult to identify pharmacologically due to the lack of specific ERK1 or ERK2 
inhibitors (e.g. MEK1/2 inhibitors such as PD98059 and U0126 reduce ERK1 and 2 
phosphorylation levels equally).  However, ERK1 and ERK2 knockout mice exhibit drastically 
differing phenotypes.  ERK1-deficient animals are viable, fertile, and grow to normal sizes.  
However, ERK1 plays a specific role in the development of thymocytes, as mature thymocytes 
were reduced by half in the ERK1-deficient animals (Pages et al., 1999).  Furthermore, ERK1-
deficient animals exhibit enhanced synaptic plasticity and learning in striatal-mediated tasks 
(Mazzucchelli et al., 2002), but not in hippocampal- or amydgala-dependent tasks (Selcher et al., 
2001).  Conversely, ERK2-deficient animals are embryonic lethal, indicating that ERK2 is 
critical for overall cellular function and embryonic development and that ERK1 cannot 
compensate for the loss of ERK2 (Mazzucchelli et al., 2002).  The determination of role of 
specific JNK isoforms in normal functioning has been similarly constrained by lack of specific 
inhibitors.  The generation of specific JNK isoform knockouts and double knockouts has 
revealed that the loss of single isoforms can impact development.  While JNK1, JNK2, and 
JNK3 single knockouts are overtly viable, JNK1 knockouts display malformations of the anterior 
commisure and a generalized disruption in microtubule assembly in neurons (Chang et al., 2003).  
Interestingly, JNK1 knockouts feature decreased adiposity and greater insulin sensitivity than 
normal mice (Himosumi et al., 2002).  JNK1/JNK2 double knockouts display alterations in brain 
development due to both increased and decreased apoptosis in various subregions of the neural 
tube but are ultimately embryonically lethal (Kuan et al., 1999).  Finally, hippocampal neurons in 
JNK3 knockout mice are resistant to apoptosis during excitotoxicity (Yang et al., 1997).  Thus, 
10 
 specific isoforms within each MAPK family may indeed have distinct and possibly opposing 
functions, and these subtleties in function are not typically dissociable in the majority of studies 
that use inhibitors that reduce the function of all isoforms equally.  This caveat must be held in 
mind when interpreting results using inhibitors of upstream kinases that regulate these MAPK 
family members.    
 For ERK1/2, a generalized phosphorylation consensus sequence in target proteins is Pro-
X-Ser/Thr-Pro (Davis, 1993).  While this consensus sequence confers some specificity to 
ERK1/2 action, ERK1/2-dependent phosphorylation of target proteins is also dependent on a 
complex set of interactions that involve the physical association of ERK1/2 with scaffolding 
proteins and other ERK1/2 binding proteins in various compartments of the cell.  Thus, the 
physical restriction of ERK1/2 and other MAPKs to cytosolic scaffolds may restrict MAPK 
functioning to cytoplasmic targets in various cell types and in varying conditions (Morrison and 
Davis, 2003).  ERK1/2-dependent phosphorylation of nuclear targets is largely responsible for 
the effects of ERK1/2 activation on gene transcription.  Although the mechanism remains to be 
fully delineated, nuclear translocation of active ERK1/2 is an important event in ERK-dependent 
signal transduction.  This occurs in part by dimerization of two activated ERK molecules and the 
subsequent uptake of this complex into the nucleus (Khokhlatchev et al., 1998).  However, 
monomeric ERK can passively diffuse through the nuclear pore, as dimerization-deficient ERK 
mutants enter the nucleus following mitogenic stimulation, while the same ERK mutants fused to 
β-gal do not (Adachi et al., 1999).  An intriguing mechanism by which ERK is transported out of 
the nucleus was revealed by both general inhibitors of nuclear export and by microinjection of 
ERK into the nucleus (Adachi et al., 2000).  Coinjection of MEK1/2, but not a mutant MEK1/2 
that was unable to physically interact with ERK1/2, allowed for nuclear export of ERK.  
11 
 Furthermore, introduction of a peptide corresponding to the ERK1/2 binding site blocked the 
ability of MEK1/2 to initiate nuclear export (Adachi et al., 2000).  These data represent 
compelling evidence for an active role of MEK1/2 in the export of ERK1/2 to the cytoplasm, but 
the functional consequences of this mechanism have not been investigated.  The dynamics 
governing the shuttling of both inactive and active ERK into and out of the nucleus are still not 
fully understood and remain a subject of debate. 
 The list of identified nuclear targets of ERK1/2 has remained fairly small.  Most 
identified targets are transcription factors, such as CREB, Elk-1, and the AP-1 complex, 
underscoring the importance of active ERK1/2 translocation to the nucleus in the mediation of 
signaling events that lead to changes in gene transcription.  Furthermore, ERK may affect 
transcription indirectly via the activation of cytoplasmic targets, such as p90 ribosomal S6 kinase 
(RSK), that translocate into the nucleus and phosphorylate transcription factors that include the 
estrogen receptor, c-Fos, and CREB (Frodin and Gammeltoft, 1999).  However, some nuclear 
targets for ERK1/2 are regulators of ERK1/2 activity themselves.  For example, ERK1/2-
dependent phosphorylation of the phosphatase MKP1 leads to stabilization of the protein and 
facilitates ERK1/2 dephoshorylation (Brondello et al., 1999).  This finding has led to an 
increasing focus on the nucleus as an important site of ERK1/2 signal termination (Volmat et al., 
2001; Pouyssegur and Lenormand, 2003).        
 
2.2.2. Importance of both temporal and spatial pattern of ERK activation in 
physiological outcome and regulation 
  
 MAPK activation represents a point of convergence and integration in the information 
processing of the cell.  For example, hormones and other ligands bind to a wide variety of 
12 
 receptors and can lead to ERK1/2 activation, yet cellular responses to those different factors can 
vary from proliferation to differentiation.  Thus, the information contained in the MAPK module 
must be more complex than a simple "on/off" switch.  Information coding in the ERK1/2 
pathway, and MAPK pathways in general, is the result of a complex interplay of both temporal 
and spatial patterning, as well as cross-talk with other signaling modules.  One well characterized 
example of the dependence on the temporal pattern of ERK activation in the determination of 
biological outcome is the diametrically opposed effect of EGF and NGF in PC12 cells.  In this 
system, EGF stimulates proliferation and causes a brief activation of ERK, while NGF induces 
differentiation and is characterized by a more prolonged, sustained pattern of ERK activation 
(Marshall, 1995).  As mentioned above, the association of ERK1/2 with different anchors can 
alter the subcellular localization of active ERK, and ERK translocation is often critical for effects 
on gene transcription.  For example, β-arrestin plays an important role in the signal transduction 
of several G-protein coupled receptors (GPCRs) by recruiting and maintaining ERK1/2 in the 
cytoplasm.  Thus, receptors with higher affinities for β-arrestin lead to an increase in cytoplasmic 
ERK1/2 signaling, and a decrease in ERK1/2 nuclear translocation, upon activation when 
compared to receptors that operate independently of β-arrestin (Tohgoet et al., 2003).  Recently, 
the identification of PEA-15 as novel, soluble, and cytoplasmic ERK1/2 binding protein has shed 
light on the complexities of ERK1/2 signaling.  PEA-15 expression can block ERK translocation 
via direct protein-protein interactions without affecting the activity of ERK (Formstecher et al., 
2001).  Thus a complex interaction of signal intensity, signal duration, and signal localization 
within the cell, truly a three-dimensional integration, determines the specific information coded 
within the activation of a MAPK module.    
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 2.2.3.  Role of MAPKs during cellular stress 
 
 MAPKs are activated by numerous stressors, including oxidative stress, in a wide range 
of tissues including the heart, lungs, skeletal muscle, liver, kidney, and brain.  Early reports 
linked such stressors as heat and osmotic shock, UV irradiation, and exposure to DNA-damaging 
agents or inflammatory cytokines with the activation of either JNK or p38 MAPKs (Kyriakis and 
Avruch, 1996; Robinson and Cobb, 1997).  Furthermore, early studies tended to associate 
ERK1/2 activation with cellular survival and p38 / JNK activation with cell death in a variety of 
model systems, including neurotrophin rescue of serum-starved PC12 cells (Xia et al., 1995) and 
H2O2 treatment of HeLa cells (Wang et al., 1998).  This led to a fairly simplistic, but quite 
influential, view that the balance of activation between p38 / JNK and ERK regulated cell death 
in a directly opposing manner.  It is now clear that the regulation of cell death by MAPKs is far 
more complex.  More recent studies have demonstrated an important cytoprotective role of both 
p38 (Lee et al., 2003) and JNK activation (Andreka et al., 2001) in a variety of model systems, 
and conversely, and increasing number of studies have demonstrated ERK-dependent cell death 
(Stanciu et al., 2000; Chu et al., 2004).  Thus the view that various classes of MAPKs have 
specific, predetermined roles in regulating cell death is quickly waning.  The outcome of MAPK 
recruitment during cellular stress is more likely due to the complex interaction of MAPK 
members with scaffolds and the temporal and spatial pattern of activation, as discussed above, 
and can likely shift the information coded within a specific pathway between such diametric cell 
responses as cellular survival or death.   
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 2.2.4.  ERK signaling during neuronal stress – Neurotoxicity or Neuroprotection? 
 
 As would be predicted from the discussion above, ERK1/2-dependent signaling during 
stress-induced neurodegeneration has not consistently been shown to function solely as a pro-
survival or a pro-cell death response.  For example, the activation of ERK1/2 has been shown to 
underlie the protective effect of growth factor rescue of serum-starved neuronal cultures (Xia et 
al., 1995) and in an in vivo rat model of hypoxia-ischemia (Han and Holtzman, 2000).  In several 
other models of toxicity, ERK1/2 activation has been shown to be necessary for neuronal 
survival, such as in the BDNF-mediated rescue of camptothecin-treated cortical neuronal 
cultures (Hetman et al., 1999).    
 However, an increasing number of studies have now demonstrated that ERK1/2 
activation during neuronal stress is necessary for neurotoxicity.  Glutamate-induced oxidative 
toxicity (Stanciu et. al., 2000; Levinthal and DeFranco, 2004), zinc toxicity (Seo et al., 2001), Fe 
/ amyloid β toxicity (Kuperstein and Yavin, 2002), focal ischemia (Alessandrini et al., 1999; 
Noshita et al., 2002), traumatic brain injury (Mori et al., 2002), seizure-induced neurotoxicity 
(Murray et al., 1998), 6-hydroxydopamine toxicity (Kulich and Chu, 2001), 
methylisothiazolinone and Zn  toxicity (Du et al., 2002), and okadaic-acid treatment of 
hippocampal slice cultures (Runden et al., 1998) have all been shown to display ERK-dependent 
neuronal cell death.  However, it is interesting to note that the role of ERK1/2 recuitment can be 
different even within the same cell type, as forced activation of ERK1/2 protects HT22 cells 
from serum withdrawal, but not from glutamate-induced oxidative toxicity (Rossler et al., 2004).   
 The divergent roles of ERK1/2 in various neurotoxicity models are likely due to the 
heterogeneity in the temporal and spatial pattern of ERK1/2 activation and the manner in which 
this pattern alters the transcription of specific target genes.  An emerging pattern appears to 
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 associate transient ERK1/2 activation with neuroprotection (i.e. in growth factor rescue of 
neurons) and sustained, prolonged ERK1/2 activation with neurotoxicity.  However, this 
assertion may be overly simplistic, and more work will be needed to firmly establish a given 
temporal and spatial profile of ERK activation with such specific and divergent functional 
outcomes.  With the advent of gene array and interference RNA technology, studies of the 
differential patterns of gene expression that occur with such divergent profiles of ERK1/2 
activation, combined with studies of the functional role of identified genes, is likely to contribute 
greatly to our understanding of role of ERK1/2 signaling during neurotoxicity. 
  
2.2.5.  Cross-talk with other pathways 
 
 The MAPK modules are integrated with other signaling pathways and engage in "cross-
talk".  In neurons, the activation of several pathways can be linked to the activation of ERK1/2.  
For example, in PC12 and hippocampal neurons, Ca2+ and PKA-dependent CRE-mediated gene 
transcription was shown to require ERK1/2 activation, and ERK1/2 translocation was dependent 
upon PKA activity (Impey et al., 1998).  Furthermore, ERK1/2 activity can be dependent upon 
PKC activation as demonstrated in phorbol ester-induced dendritic spine formation in cultured 
hippocampal neurons (Goldin and Segal, 2003).   
 Phosphatidylinositol 3-kinase (PI3K) is an enzyme that phosphorylates the D3 position of 
various lipid inositols to form PI3, PI3,4, and PI3,4,5.  PI3K activation is generally linked to both 
tyrosine kinase and G-protein coupled receptors, and the PI3K-dependent production of PI3,4,5 
is required by the 3-phosphoinositide dependent kinase 1 (PDK1) to phosphorylate and 
activation of another important kinase, Akt.  Thus in most instances, PI3K activity results in Akt 
phosphorylation, and these kinases comprise a well-described signaling module.        
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  The PI3K-Akt and Raf-MEK-ERK pathways are functionally coupled in many instances, 
and across many cell types.  Early reports found that PI3K can act as an intermediate in G-
protein-associated signaling upstream of Ras activation and that PI3K activity was thus 
necessary for the eventual recruitment of the Raf-MEK-ERK pathway (Hawes et al., 1996; 
Lopez-Ilasaca et al., 1997).  In neurons, there is much evidence to support significant crosstalk 
between the PI3K and ERK pathways in other non-G-protein mediated signaling events.  For 
example, in striatal cultures, ERK signaling downstream of AMPA and NMDA receptor 
activation was shown to depend upon PI3K activity (Perkinton et al., 1999, 2002).  PI3K was 
also demonstrated to be required for the NGF-induced sustained activation of ERK during PC12 
differentiation (York et al., 2000).  Furthermore, PI3K activation was shown to occur upstream 
of ERK activation in vivo in a rat model of associative learning (Lin et al., 2001).  Finally, PI3K 
activity has been shown to be required for the recruitment of ERK in the absence of direct 
ligand-receptor interactions.  For example, ERK1/2 activation due to hydrogen peroxide-induced 
oxidative stress in primary cortical neuronal cultures can be PI3K dependent (Crosswaite et al., 
2002).  Thus there appears to exist a mechanism for functional coupling of the PI3K and ERK 
pathways in neurons, with the potential for PI3K to act as a required upstream activator for the 
transduction of a variety of signals.    
 
2.3. Phosphatases 
 
2.3.1.  Major classes of phosphatases 
  
 Phosphatases are enzymes that hydrolyze phosphorylated protein, lipid, and small 
molecule substrates and act in opposition to the multitude of kinases in the cell.  Phosphatases 
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 that are directed against protein substrates have received considerable attention due to their 
potential role in the regulation of cellular signaling events.  Most protein phosphatases can be 
classified into one of three general groups according to their specificity of action.  These groups 
are the Ser/Thr-, Tyr-, and dual-Ser/Thr and Tyr-directed phosphatases and are also referred to as 
protein phosphatases (PPs), protein tyrosine phosphatases (PTPs), or dual-specificity 
phosphatases (DUSPs or DSPs), respectively.  Historically, the PPs were among the earliest to be 
identified (1970's), followed by PTPs (1980's), and finally, DSPs (1993 to the present), and thus 
the understanding of the regulation of these classes of enzymes is greatest for the PPs, while the 
mechanisms governing PTP and DSP regulation are only beginning to become clear.   
 
2.3.2.  Substrate specificity and role as important regulators of cellular signaling 
 
 PPs, PTPs, and DSPs act upon a wide variety of proteins targets that include structural 
elements, metabolic enzymes, transcription factors and general transcriptional machinery, 
receptors, ion channels, adapter proteins, and signaling molecules.  However, specific 
phosphatases act on restricted subsets of targets, and the mechanisms governing this specificity 
of action are active areas of study.  Most PTPs share a common modular structure in which 
regulatory and binding domains are localized in the N-terminal region, while the conserved 
catalytic domain is located in the C-terminal region.  A targeted, physical interaction of these 
phosphatases with a substrate protein appears to lead to specificity for many PTPs, which display 
great heterogeneity in amino acid sequences in the N-terminal region.  For example, the PTP 
SHP-2 contains an SH2 domain that specifically targets the phosphatase to phospho-tyrosine 
moieties on receptor tyrosine kinase molecules (Neel et al., 2003), thus linking the recruitment of 
these phosphatases to the auto-phosphorylation reactions that occur at receptor tyrosine kinases 
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 when bound to ligand.  For other PTPs of the membrane-bound, receptor class (i.e. the receptor 
protein tyrosine phosphatase α [RPTPα]), extracellular fibronectin-type and immunoglobulin 
domains are involved in the regulation of intracellular phosphatase domains (Denu and Dixon, 
1998).  For example, RPTPα can act as a transducer of mechanical force and extracellular matrix 
(ECM) contact by stabilizing αv/β3 integrin-cytoskeleton interactions (von Wichart et al., 2003), 
and this interaction leads to RPTPα-dependent dephosphorylation of phospho-tyrosine residues 
on Src kinase.  However, RPTPα does not appear to directly bind ECM proteins but acts in cis 
with other membrane receptors (von Wichart et al., 2003).  To date, the endogenous ligands for 
RPTPs have not been well characterized, and only one endogenous ligand has been identified for 
RPTPβ, the cytokine pleiotrophin (Meng et al., 2000).  Recently, an intriguing study identified 
the Helicobacter Pylori vacuolating toxin VacA as a potent xeno-ligand for RPTPβ (also known 
as PTP-zeta) (Fujikawa et al., 2003).  In this study, RPTPβ-deficient animals were shown to be 
insensitive to the formation of VacA-dependent gastric ulcers during H. Pylori infection, while 
gastric pleiotrophin administration in wild type animals caused ulceration.  These findings 
clearly establish aberrant RPTP-β activation as a causative factor in the development of gastric 
ulceration, highlighting the importance of phosphatase dysregulation in pathology.      
 Within the PTPs and DSPs, an important domain referred to as the kinase-interaction 
motif (KIM) appears to confer great specificity to these enzymes and targets them to specific 
kinases, such as ERK1/2 and other MAPKs (Tanoue et al., 2002).  Interestingly, KIM domains 
are found within multiple members of MAPK modules, including upstream activators (e.g. 
MEKs) as well as downstream effectors (e.g. MAPKAPKs), and appear to contribute to the 
affinity of these molecules for specific MAPK members (Tanoue and Nishida, 2003).  The KIM 
domains of multiple MKPs have been identified, and due to the specificity of the protein-protein 
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 interactions at this site, disruption of KIM-MAPK interactions are an intriguing site for 
therapeutic development using small peptide inhibitors. Table 1 shows the sequence of known 
KIM domains in several MEK/MKKs, MAPKAPKs, MAPK-directed phosphatases, and 
transcription factors, along with the specific MAPKs that interact with that site (adapted from 
Tanoue et al., 2000; Tanoue and Nishida, 2003).  Note that all of these sites contain several basic 
residues that are necessary for binding (indicated in bold).      
Class of  
Docking Protein  
Specific 
Protein 
Kinase Docking Site  Specific MAPK 
Target 
MAPKK MEK1 MPKKKPTPIQLNPNP ERK 
 MEK2 MLARRKPVLPALTINP ERK 
 MKK3 KGKSKRKKDLRI p38 
 MKK6 SKGKKRNPGLKIP p38 
 SEK1/MKK4 QGKRKALKLNF JNK, p38 
 MKK7 EARRRIDLNLDISP JNK 
 MEK5 LKKSSAELRKIL ERK5 
MAPKAPK RSK1 SSILAQRRVRKLPSTTL ERK 
 RSK2 RSTLAQRRGIKKITSTAL ERK 
 RSK3 SSNLAQRRGMKRLTSTRL ERK 
 MNK1 KSRLARRRALAQAGRSRD ERK p38 
 MNK2 QSKLAQRRQRASLSATPV ERK 
 MSK1 KAPLAKRRKMKKTSTSTE ERK, p38 
 MAPKAPK2 NPLLLKRRKKARALEAAA p38 
 MAPKAPK3 NRLLNKRRKKQAGSSSAS p38 
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  PRAK NNPILRKRKLLGTKPKDS p38 
 RSKB NAPLAKKRKQKLRSATAS p38 
PTP EC-PTP GLQERRGSNVSLTLDM ERK 
 He-PTP RLQERRGSNVALMLDV ERK 
 STEP GLQERRGSNVSLTLDM ERK 
MKP MKP1 RFSTIVRRRAKGAKGAG ERK, p38, JNK 
 MKP2 RCNTIVRRRAKGSVLE ERK, p38, JNK 
 MKP3 PGIMLRRLRKGNLPIR ERK 
 MKP4 LPALLLRRLRRGSLSVR ERK 
 MKP5 CADKISRRRLQQGKTIV p38, JNK 
 Pyst2/MKP-X PGLMLRRLRKGNLPIR ERK 
 PAC1 PWNALLRRRARARGPP ERK, p38, JNK 
 B23 LNSVVLRRARGGAVSA ERK 
 M3/6 / hVH5 SKLVKRRLQQGKVTI p38, JNK 
Transcription 
factor 
MEF2A NSRKPDLRVVIPPSSK p38 
 SAP-1 RSKKPKGLGLAPTLVIT ERK, p38 
 Elk-1 KGRKPRDLELPLSPSLL ERK, p38 
Table 1  MAPK-docking sites on MAPK interacting molecules 
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 2.3.3. Mechanisms of catalysis 
   
 Two distinct mechanisms of catalysis are employed by the PPs and the PTP/DSPs.  
Dependence upon metal centers typify the PPs in general, and this metal center activates a water 
molecule in the active site to promote a one-step phosphate hydrolysis reaction.  The PPs can be 
divided into PPP and PPM subclasses depending upon their dependence for various specific 
metals in the catalytic center.  PPPs such as PP1, PP2A, and PP2B (calcineurin), are dependent 
upon a di-nuclear ion center that is composed of Mn, Fe and/or Zn in various combinations 
(Nishito et al., 1999), while PPMs, such as the PP2C-like phosphatases, are dependent on Mg 
and/or Mn (Zhou et al., 2002).  The PTPs and DSPs both share a canonical HC(X)5R motif in 
their active sites, and the cysteine residue is absolutely critical for enzymatic function.  Catalysis 
is dependent upon the formation of a stable phosphoryl-intermediate that is stabilized by 
surrounding residues, including an important, conserved arginine.  Another conserved asparatic 
acid functions as a general acid/base to complete the hydrolysis reaction (Denu and Dixon, 
1998).  The binding pockets of PTPs have been shown to be ~9Å, while those of the DSPs tend 
to be shallow at ~6Å.  This difference is thought to contribute to the differential specificity for 
tyrosine and serine/threonine phosphates – the shorter serine/threonine residues may not gain 
access to the deeper binding pocket of the PTPs and are therefore spared from hydrolysis (Denu 
and Dixon, 1998).   
 For many PTPs, physical interaction via the KIM domain of the phosphatase and the 
target protein is required for conformational changes in the phosphatase that significantly 
increase enzymatic activity.  This mechanism appears to be fairly generalized across the MKPs 
(Farooq et al., 2003; Farooq and Zhou, 2004), but has been most studied with MKP3.  For 
example, ERK2 binding to MKP3 via the KIM domain on MKP3 (Nichols et al., 2000) stabilizes 
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 the active conformation of the active site cysteine (Farooq et al., 2001) and results in an 
approximately 100-fold increase in enzymatic activity (Fjeld et al., 2000).  Interestingly, MKP3 
appears to first dephosphorylate the phospho-threonine residue within dually phosphorylated T-
X-Y motif on ERK2, dissociate, and subsequently reassociate with monophosphorylated ERK2-
phoshotyrosine (Zhao and Zhang, 2001).  Importantly, MKP3 has been found to engage in 
intramolecular dephosphorylation of ERK with a binding stoichiometry of 1:1 (Kim et al., 2003).  
Thus ERK-binding dependent increases in MKP3 activity result in the dephosphorylation of the 
same bound ERK molecule, and not a freely soluble secondary ERK molecule.  These 
considerations have important implications for the negative regulation of ERK given that active 
ERK1/2 forms dimers in solution, which may be resistant to inactivation by MKP3.  Actve 
ERK1/2 dimers translocate into the nucleus, and ERK inactivation may be driven by dimer 
dissociation and subsequent binding to MKPs.       
 
2.3.4. MAPK-directed phosphatases 
 
 While protein phosphatases are directed against a vast array of targets, an increasing 
number of studies have focused on the regulation and physiological role in both normal and 
abnormal signaling events of a subset of phosphatases targeted to various MAPK members.  
These phosphatases, some of which are targeted only to specific MAPK family members, act as 
important negative regulators and can function in a negative feedback loop to limit MAPK 
activation.  In a variety of cell types, ERK1/2 activity is regulated by several phosphatases 
including PP2A (Zhou et al., 2002), PTP-SL / He-PTP (Pulido et al., 1998; Nika et al., 2004), 
PTP-ER (Karim and Rubin, 1999), STEP (Pulido et al., 1998), and the cdc25s (Vogt et al., 
2003), among numerous others.  An emerging group of specific-MAPK phosphatases, or MKPs, 
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 are DSPs that remove both phosphatases from the T-X-Y activation motif in the P-loops of 
several MAPK members.  MKPs show differing specificities for the MAPKs, but some are 
exquisitely specific for only ERK1/2, such as B23, MKP3, and MKP-X (Mustelin et al., 2002).  
Table 2 lists some of the known MAPK phosphatases and their substrate specificities (adapted 
from Mustelin et al., 2002) that have activity against ERK1/2 and shows the various MAPK 
specificities of other identified MKPs. 
 While the expression patterns for the various MKPs have not been fully completely 
delineated, MKPs clearly have been shown to play important physiological roles in a wide 
variety of organ systems.  Well described roles for MKPs are found within the hematopoetic and 
immune systems.  For example, the PTP member He-PTP has specificity for ERK1/2, and is 
involved in signaling events in hematopoietic cells (Gronda et al., 2001), and a key component of 
the T-cell antigen receptor (TCR) signaling complex, ZAP-70, phosphorylates and activates the 
phosphatase VHR to downregulate ERK1/2 in response to ligand binding at the TCR (Alonso et 
al., 2003).  In neurons, STEP is another PTP that plays an important role in NMDA receptor 
signaling (Paul et al., 2003).  Furthermore, PTP-ER has been shown to be necessary for 
photoreceptor development via its regulation of ERK (Rintelen et al., 2003).  Interestingly, both 
MKP1 and MKP3 expression is potently increased in the hippocampi of rats following global 
ischemia (Kawahara et al., 2004).  Clearly, more studies of the tissue specific expression pattern 
of MAPK phosphatases will be needed to elucidate their role in both normal functioning and 
pathology. 
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 MKP Substrate Subcellular 
Localization 
MKP1 ERK, JNK, p38 Nucleus 
MKP2 ERK, JNK, p38 Nucleus 
MKP3 ERK Cytoplasm 
MKP4 ERK>JNK=p38 Cytoplasm>Nucleus 
MKP5 JNK, p38α and β Cytoplasm=Nucleus 
MKP6 ERK, JNK Cytoplasm 
MKP7 JNK, p38α and β Cytoplasm 
MKP-X ERK Cytoplasm 
PAC1 ERK, p38 Nucleus 
B23 ERK Nucleus 
VHR ERK, JNK Cytoplasm 
M3/6 JNK, p38 Cytoplasm=Nucleus 
PTP   
He-PTP ERK Cytoplasm 
EC-PTP ERK Cytoplasm 
STEP ERK Cytoplasm 
 
Table 2 MAPK substrate specificities and subcellular localization of various MKPs  
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 2.4. Oxidation Mediated Inhibition of Phosphatases 
  
2.4.1. Sensitivity of PTPs and DSPs to redox inhibiton and mechanisms of inhibition 
 
 Cellular redox conditions can have a profound effect on signal transduction pathways, 
and over the past several years, a growing body of work has identified a unique sensitivity of 
PTP and DSP function to changes in redox conditions.  This linkage between ROS and signaling 
has led to a novel view of ROS as potential signaling molecules themselves in a mechanism now 
referred to as oxidative signaling.  Thus oxidative conditions may lead to phosphatase inhibition 
and alter the steady state level of phosphorylation on important signaling molecules, such as 
kinases and transcription factors.  
 PTPs and DSPs share significant sequence homology in their catalytic sites, possessing 
the canonical HC(X)5R motif metioned above.  Early studies of the effects of oxidation on 
phosphatase function identified the catalytic cysteine within the active site as being particularly 
susceptible to oxidation with a measured pKa of 5.5 (Denu and Tanner, 1998).  Thus, at 
physiological pH, the catalytic cysteine within these phosphatases is approximately 1000-fold 
more deprotonated than free cysteine (pKa = 8.5) and ~300 times more deprotonated than the 
cysteine residues found in most proteins (pKa ~8).  This uniquely enables PTPs and DSPs to 
function effectively as redox sensors in the cell.   
 The mechanisms that govern redox modification of phosphatase function are varied.  
Oxidation of the catalytic cysteine is believed to progress through a step-wise series of oxidation 
reactions that begin with the interaction of H2O2 or other oxidants with the thiolate anion (i.e. R-
S-) to yield a potentially stable sulfenic acid (i.e. –SOH) intermediate.  This modification is 
reversible by thiol reducing agents (Denu and Tanner, 1998).  Further oxidation of the sulfenic 
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 acid can yield sulphinic acid (i.e. –SO2H) and sulphonic (i.e. –SO3H) forms that are irreversibly 
oxidized.  However, the sulfenic acid intermediate represents a point of divergence in redox-
dependent phosphatase inhibition, as several different phosphatases display a variety of 
mechanisms of reversible oxidation.  For example, several phosphatases can form a stable 
intramolecular disulphide between vicinal cysteines within the active site.  This mechanism has 
been demonstrated in LMW-PTP (Chiarugi et al., 2001) and Cdc25C (Savitsky and Finkel, 
2002).  Oxidation dependent changes in the catalytic cysteine may also lead to siginificant 
conformational changes that affect function.  The oxidation of the catalytic cysteine in RPTPα 
leads to a novel intramolecular interaction between the C-terminus and the spacer region to 
stabilize RPTPα dimers, resulting in enzymatic inactivation (Blanchetot et al., 2002).  Finally, an 
intriguing stable-intermediate form of oxidized PTP1B was crystallized by two groups 
independently.  In this protein, oxidation of the catalytic cysteine results in the formation of a 
stable sulphenyl-amide between the cysteine and the main chain nitrogen of the adjacent residue 
(Salmeen et al., 2003; van Montfort et al., 2003).  It is difficult to predict which mechanisms 
predominate in a given phosphatase, but it appears that many phosphatases have evolved 
mechanisms to preserve function by enabling the formation of stable, oxidized intermediate 
forms that protect the enzyme from irreversible oxidation.   
 Much less is known about the mechanisms that govern oxidative inhibition of ser/thr 
protein phosphatases such as PP1, PP2A, PP2B.  Recently, PP2A has been shown to be sensitive 
to H2O2 in both aging fibroblasts (Kim et al., 2003) and brain tissue (Foley et al., 2004).  These 
studies both find that PP2A activity is inhibited by oxidative stress in a thiol-reducant reversible 
manner, implying that the oxidation of cysteine residues within the protein, or associated 
subunits, leads to inhibition.  Studies using the bacteriophage λ protein phosphatase, a general 
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 model for all protein phosphatase metalloenzymes, have shown that multiple combinations of 
metal species can exist in the metal center and are susceptible to subtle alterations in redox 
conditions (Reiter and Rusnak, 2004).  Interestingly, PP1C-α was found to be sensitive to 
oxidation in vitro due to both thiol-oxidation and the oxidation of the metal center (Kim et al., 
2003), while PP2B was similarly inhibited by oxidation of two vicinal cysteines as well as by 
identified redox changes (i.e. Fe2+-Zn2+ oxidized to Fe3+-Zn2+) in the metal center (Bogumil et 
al., 2000; Namgaladze et al., 2002).  Thus, both alterations in metal chemistry and thiol-
oxidation are likely mechanisms by which oxidative stress may impact the activity of the PPs.     
  
2.4.2.  ROS mediated inhibition of phosphatases in vivo 
 
 ROS-mediated inhibition of phosphatase function may act within normal signaling events 
or can be involved in cellular pathology.  The transduction of the growth receptors has been a 
model system for the study of localized ROS production and transient, reversible phosphatases 
inhibition.  In Rat-1 cells, PDGF-treatment and PDGF receptor activation is associated with the 
brief production of ROS and a coincident inhibition of specific phosphatases, including SHP-2 
(Meng et al., 2002).  Phosphorylated ERK levels increased in a ROS-dependent manner, strongly 
suggesting that the inactivation of specific phosphatases plays an important and active role in this 
process.  ROS-dependent inactivation of phosphatases has also been demonstrated in several 
model systems, including cell adhesion in several T-cell (Laakko and Juliano, 2003) and 
fibroblast cell lines (Chiarugi et al., 2003), ligand-induced Rho-GTPase dependent changes in 
actin cytoskeleton (Nimnual et al., 2003), and EGF-receptor activation in a breast cancer cell line 
(Reynolds et al., 2003).  While innumerable studies have investigated ROS-dependent toxicity, 
abnormal recruitment of signaling pathways via ROS-dependent phosphatase inhibition has 
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 remained unexplored.  This mechanism could be an important feature of MAPK activation that 
occurs during oxidative stress, and phosphatases could very well be the redox sensors that 
initiate aberrant signaling in this context.   
 
2.5. THE MODEL SYSTEM: Glutamate-induced oxidative toxicity  
 
2.5.1.  The Xc- glutamate / cystine antiporter 
 
 Extracellular glutamate acts on neurons via several pathways that include binding to 
ionotropic receptors (i.e. kainate, AMPA, and NMDA receptors), metabotropic receptors 
(mGluRs), high affinity glutamate uptake transporters, and a chloride-dependent amino acid 
antiporter (Xc-).  The Xc- system is ubiquitously expressed in mammalian cells and is involved in 
the exchange of intracellular glutamate for extracellular cystine, the oxidized, disulphide form of 
cysteine (Sato et al., 1999).  Since cystine is rapidly reduced to free cysteine in the cytoplasm, 
and intracellular glutamate concentrations are much larger than outside the cell, there is a 
considerable concentration gradient that drives this exchange.  Intracellular cysteine levels are 
dependent upon the activity of the Xc- exchanger, and free cysteine is the rate-limiting precursor 
for glutathione synthesis.  Therefore, the activity of the Xc- exchanger directly controls 
glutathione levels in the cell, and inhibition of the exchanger, by increasing extracellular 
glutamate, leads to the depletion of intracellular glutathione.  While both neurons and astrocytes 
express and utilize the Xc- system, there are no reported differences in the efficiency of this 
system between these two cell types (Allen et al., 2002).            
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 2.5.2.  Glutamate-induced oxidative toxicity in HT22 and primary immature 
cortical cultures 
 
 Glutamate-induced oxidative toxicity is a useful model system for studying the effects of 
oxidative stress on cell death that relies upon the inhibition of the Xc- system.  Several cellular 
systems have been shown to be sensitive to the effects of extracellular glutamate via this 
mechanism, including HT22 cells (Behl et al., 1995; Li et al., 1997), primary immature cortical 
cultures (Murphy et al., 1990), mature enriched cortical neuronal cultures (Schubert and 
Piasecki, 2001), PC12 cells (Froissard et al., 1997), and C6 glioma cells (Mawatari et al., 1996).  
However, the analysis in some of these systems is confounded by the presence of ionotropic 
receptors and a potential for excitotoxic cell death.  HT22 is a mouse hippocampal-derived cell 
line, immortalized with a temperature-sensitive SV-40 T antigen, which does not express 
ionotropic glutamate receptors.  Thus, this cell line is uniquely suited for studying the effects of 
glutamate-mediated Xc- inhibition and subsequent glutathione depletion.  Similarly, immature 
primary cultures of embryonic cortical cells (DIV 1-4) show a specific sensitivity to glutamate-
induced oxidative toxicity (Murphy et al., 1990).  This is due to a delay in the expression of 
functional ionotropic glutamate receptors until DIV 7 or later, when greater than 80% of cultured 
neurons display inward currents in the presence of glutamate and other agonists, such as NMDA 
(Murphy and Baraban, 1990).          
 
2.5.3.  Signaling events during glutathione depletion in HT22 and primary 
immature cortical cultures 
 
 Glutamate-induced oxidative toxicity is characterized by a gradual depletion of 
intracellular glutathione levels that occurs over several hours.  In HT22 cells, glutathione 
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 depletion leads to the activation of 12-lipoxygenase (12-LOX) upstream of a massive influx of 
Ca2+ and subsequent ROS accumulation (Li et al., 1997).  Similarly, toxicity in primary cortical 
cultures is also dependent upon the activation of 12-LOX and rises in intracellular Ca2+ (Li et al., 
1997; Stanciu et al., 2000).  The characteristics of the Ca2+ channels that are involved in Ca2+ 
influx have not been identified.     
 HT22 cells have remained a standard neuronal cell line for the study of glutamate-
induced oxidative toxicity, but the signaling events that underlie toxicity in these cells remains 
somewhat controversial.  Several studies have demonstrated that glutamate-induced oxidative 
toxicity is dependent upon the activity of the phospholipase C (PLC) isoform 
phosphatidylcholine-specific PLC (PS-PLC) and protein kinase C (PKC) (Li et al., 1998; Maher, 
2001).  However, while one study concluded that multiple MAPK members are involved in 
toxicity and that ERK may play a protective role (Maher, 2001), we have found that the 
development of glutamate-induced oxidative toxicity depends specifically upon the persistent 
activation of ERK1/2.  This finding was perhaps the first reported finding of a neurotoxic role for 
ERK1/2 (Stanciu et al., 2000), and has been replicated in both HT22 cells and in immature 
primary cortical cultures (Satoh et al., 2000; Stanciu et al., 2000; Stanciu and DeFranco, 2002; 
Levinthal and DeFranco, 2004).  Thus, MEK inhibitors such as U0126 protect both HT22 cells 
and primary cortical neurons from oxidative toxicity.  The exact targets of ERK1/2 activation 
that are required for oxidative toxicity have not been identified. 
 
3. THESIS GOALS 
 
 The work presented here was initiated with two broad research goals.  Because 
glutamate-induced oxidative toxicity in both HT22 and immature primary cortical cultures 
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 previously had been shown to be dependent upon the recruitment of ERK, I focused on studying 
factors that determined ERK activation in these cells during oxidative toxicity.  Early studies 
with inhibitors revealed a unique coupling of the PI3K pathway to eventual ERK activation in 
primary immature cortical cultures and protection of neurons from oxidative toxicity via PI3K 
inhibition (Chapter 1).  However, I also focused on the regulation of endogenous phosphatases 
during oxidative stress and the impact of overexpression of a specific ERK-phosphatase, MKP3, 
on neuronal oxidative toxicity.   
 First, I sought to determine whether oxidative stress altered the activity of phosphatases 
that are targeted to the ERK MAPK pathway, the biochemical nature of those phosphatases, and 
the potential mechanisms of redox modification.  Due to the wealth of information implicating 
oxidative stress-induced phosphatase inhibition, I hypothesized that the persistent ERK 
activation observed during oxidative toxicity was due to the specific inhibition of ERK-directed 
phosphatases and a loss of negative feedback on the ERK MAPK signaling pathway.  The results 
from these studies are presented in Chapter 2. 
 Second, I sought to manipulate ERK activity and subcellular localization to specifically 
determine whether ERK translocation to the nucleus was indeed required for neuronal oxidative 
toxicity.  The ERK-specific phosphatase MKP3 previously had been shown to be a useful tool to 
inhibit the activity (MKP3 WT overexpression) and to force the cytosolic localization (MKP3 
C293S overexpression) of ERK in a landmark study that characterized this approach in 
fibroblasts (Brunet et al., 1999).  I hypothesized that MKP3 WT overexpression would be 
neuroprotective in both HT22 cells and primary immature cortical neurons by reducing the levels 
of phosphorylated, active ERK.  Furthermore, studies in our laboratory suggested that ERK 
nuclear translocation was associated with oxidative toxicity in HT22 cells.  Thus, I hypothesized 
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 that the physical restriction of active ERK to the cytoplasm would directly impact the 
development of glutamate-induced oxidative toxicity by denying active ERK access to 
downstream nuclear targets.  The data from these genetic manipulation studies is presented in 
Chapter 2.   
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 4. CHAPTER 1: Transient Phosphatidylinositol-3 Kinase Inhibition Protects 
Immature Primary Cortical Neurons from Oxidative Toxicity via Suppression of 
Extracellular-Signal Regulated Kinase Activation 
 
4.1. SUMMARY 
 Oxidative stress has been shown to underlie a diverse range of neuropathological 
conditions.  Glutamate-induced oxidative toxicity is a well-described model of oxidative stress-
induced neurodegeneration that relies upon the ability of extracellular glutamate to inhibit a 
glutamate / cystine antiporter, which results in a depletion of intracellular cysteine and the 
blockade of continued glutathione synthesis.  Glutathione depletion leads to a gradual, toxic 
accumulation of reactive oxygen species (ROS).  We have previously determined that glutamate-
induced oxidative toxicity is accompanied by a robust increase in activation of the mitogen-
activated protein kinase (MAPK) member extracellular-signal regulated kinase (ERK) and that 
this activation is essential for neuronal cell death.  This study demonstrates that delayed ERK 
activation is dependent upon the activity of phosphoinositol-3 kinase (PI3K) and that transient, 
but not sustained, PI3K inhibition leads to significant protection of neurons from oxidative 
stress-induced neurodegeneration.  Furthermore, we show that transient PI3K inhibition prevents 
the delayed activation of MEK-1, a direct activator of ERK, during oxidative stress.  Thus, this 
study is the first to demonstrate a novel level of cross-talk between the PI3K and ERK pathways 
in cultured immature cortical neuronal cultures that contributes to the unfolding of a cell death 
program.  The PI3K pathway, therefore, may serve opposing roles during the progression of 
oxidative stress in neurons, acting at distinct kinetic phases to either promote or limit a slowly 
developing program of cell death.   
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 4.2. INTRODUCTION 
 Neuronal cell death due to oxidative stress links such diverse conditions as Parkinson’s 
Disease, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and stroke (Coyle and 
Puttfarcken, 1993; Mattson et al., 2001).  Glutamate-induced oxidative toxicity has become an 
excellent paradigm for studying the effects of oxidative stress in primary immature neuronal 
culture (Murphy et al., 1990; Ratan et al., 1994; Li et al., 1997; Stanciu et al., 2000).  In this 
model, inhibition of a glutamate / cystine antiporter deprives cells of essential precursors for 
glutathione synthesis.  An increased load of ROS results from this glutathione depletion (Murphy 
et al., 1990; Li et al., 1997) and activates intracellular signaling events that engage an apoptotic-
like cell death program (Ratan et al., 1994).   
 The MAPK family member ERK is activated by a vast array of stimuli that impinge upon 
the cell and acts on a diverse range of cellular targets (Davis, 1993; Garrington and Johnson, 
1999; Grewel et al., 1999).  In neurons, ERK can function to either support cell survival or 
promote cell death.  ERK was originally implicated in neuronal cell survival in differentiated 
PC12 cells that required neurotrophic factor support (Xia et al., 1995), and many subsequent 
studies have confirmed its contribution to neuronal cell survival in other systems (Bonni et al., 
1999; Gonzalez-Zulueta et al., 2000; Han and Holtzman, 2000; Zhu et al., 2000).  However, in 
many other models of neuronal cell death, ERK activation has been found to be associated with 
cell death (Murray et al., 1998; Alessandrini et al., 1999; Stanciu et al., 2000; Namura et al., 
2001; Du et al., 2002; Mori et al., 2002; Noshita et al., 2002; Stanciu and DeFranco, 2002).  The 
mechanisms that underlie such diametric effects of ERK are unclear but could be based on 
differences in both the temporal and spatial pattern of ERK activation induced by the various 
treatments (Stanciu and DeFranco, 2002). 
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  The PI3K-Akt pathway has been found to consistently serve a pro-survival function in 
neurons exposed to various apoptosis-inducing stimuli (Datta et al., 1999).  These effects are 
thought to occur via Akt-mediated inactivation of Bad (Datta et al., 1997), caspase-9 (Cardone et 
al., 1998), or members of the Forkhead transcription factor family (Bonni et al., 1999), among 
others.  In neurons, there is much evidence to support significant crosstalk between PI3K and 
ERK (Perkinton et al., 1999; York et al., 2000; Lin et al., 2001; Perkinton et al., 2002; 
Crossthwaite et al., 2002), with the potential for PI3K to act as a required upstream activator of 
ERK.    
 We have previously demonstrated in immature primary cortical neurons that activation of 
ERK is necessary for glutamate-induced oxidative toxicity (Stanciu et al., 2000).  We now 
demonstrate that this ERK activation is PI3K-dependent, and that transient, but not sustained, 
PI3K inhibition leads to significant protection of neurons.  Thus, the PI3K pathway may serve 
opposing roles during the progression of oxidative stress in neurons, acting at distinct kinetic 
phases to either promote or limit a slowly developing program of cell death.  
 
4.3. EXPERIMENTAL PROCEDURES 
Primary Cortical Cultures   Cortices from embryonic day 17 Spague-Dawley rat fetuses (Hilltop 
Lab Animals, Scottdale, PA) were dissected and manually dissociated by repeated trituration 
using fire-polished glass pipettes in Hanks Balanced Salt Solution (5.4 mM KCl, 0.3 mM 
Na2HPO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 137 mM NaCl, 5.6 mM D-glucose, pH 7.4) 
without Ca2+ or Mg2+ (Invitrogen, Carlsbad, CA) followed by passage through a 40 µm cell 
strainer (Becton Dickinson Labware, Franklin Lakes, NJ) to remove clumped cells.  Cells were 
counted and plated on 50 µg/ml poly-D-lysine treated culture plates at a density of ~2.1 x 104 
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 cells / cm2.  Cell viability was routinely greater than 80% as assessed by uptake of trypan blue 
dye upon plating.  Cultures were maintained for 3-4 days in media (DMEM (Invitrogen), 10% 
fetal calf serum (Hyclone, Logan, UT), 10% Ham’s F12 Nutrient Supplement (Invitrogen), 1.9 
mM glutamine, 24 mM Hepes Buffer, and 4.5 mg/mL glucose) at 37ºC and 5% CO2.  All 
experiments were performed on DIV3-4 day old cultures to avoid the confounding effect of 
functional ionotropic glutamate receptor expression, which is not present in immature cultures, 
but which begins soon after this time period (Mizuta et al., 1998).  At this time, these cultures 
contain approximately 20% GFAP+ glial elements.   Unless otherwise stated, all chemicals and 
reagents used were purchased from Sigma Chemical Corporation, St. Louis, MO.    
 
Cell Line Culture  HT22 cells, a hippocampal cell line that is particularly sensitive to glutamate-
induced oxidative toxicity (Davis and Maher, 1994), were maintained in DMEM supplemented 
with 10% fetal calf serum (Atlanta Biologicals, Norcross, GA), 100 Units Penicillin, and 100 
µg/mL Streptomycin at 37ºC and 5% CO2.   
 
Cell Viability   Eighteen hours following the initiation of all treatments, cultures were incubated 
for 10 minutes with 6.25 µg/mL propidium iodide (PI) to visualize dead or dying PI-positive 
cells.  Cells were observed under an inverted fluorescence microscope equipped with phase 
contrast optics (Nikon Eclipse TE200), and PI-labeled and unlabeled cells were counted by a 
non-blinded observer.  The percentage of labeled cells in each field was then calculated 
(approximately 200 cells per field at 400x).  Three random fields were counted for each 
condition in at least three separate cultures.    
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 Western Blot Analysis  Cells were treated as described, scraped and collected into phosphate-
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 
7.4), pelleted at 2-3 x 103 rpm for 5 minutes, and lysed in Lysis Buffer (50mM Tris-Cl, pH 7.5, 
2mM EDTA, 100 mM NaCl, 1% NP-40, 100µM NaVO4, 100 µM NaF, 2mM DTT) 
supplemented with 5µL protease inhibitor cocktail per milliliter of lysis buffer.  Total protein 
concentrations were determined using the Bio-Rad™ Kit.  Equivalent amounts of total protein 
(either 20 or 30 µg) were separated by SDS-PAGE on 10% polyacrylamide gels and then 
transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA).  
Membranes were blocked with 5% dry milk in PBS / 0.1% v/v Tween-20 (PBST).  Membranes 
were incubated with primary antibodies (anti-phospho ERK, anti-total ERK, anti-phospho Akt, 
and anti-total Akt, all from Cell Signaling, Beverly, MA) overnight at 4ºC with 3% dry milk or 
5% BSA, washed 3x 10 minutes with PBST, and then exposed to the appropriate horseradish-
peroxidase (HRP)-conjugated secondary antibody for one hour at room temperature.  Membranes 
were again washed 3x 10 minutes with PBST, and immunoreactive bands detected by enhanced 
chemiluminescence (ECL, Amersham Biosciences, Piscataway, NJ) using standard x-ray film 
(Kodak, Rochester, NY).  Several different exposure times were used for each blot to ensure 
linearity of band intensities.    
 
MEK Kinase Activity Assay   MEK kinase activity was determined via the ability of 
immunoprecipitated MEK to phosphorylate purified, unphosphorylated GST-ERK2 protein 
using 32P-labelled ATP.  In brief, 400 µg of total lysate protein from primary immature cortical 
cultures were pre-cleared with 50 µl of a 100 mg/mL stock of protein-A Sepharose beads 
(Amersham Biosciences) for 1 hour at 4ºC on a rotating shaker.  The supernatants were then 
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 immunocomplexed with a non-specific rabbit IgG antibody (FITC-conjugated rabbit anti-sheep) 
or a rabbit polyclonal antibody directed against the N-terminal region of MEK-1 (anti-MEK1 
NT; Upstate, Lake Placid, NY) overnight at 4ºC on a rotating shaker.  The immunocomplexes 
were absorbed to 80 µL of the 100 mg/mL stock of Protein-A Sepharose beads for 2 hours at 4ºC 
on a rotating shaker, and subsequently washed twice with ice-cold Lysis Buffer (see above).  The 
pelleted beads were resuspended in 50 µl Kinase Buffer (Lysis Buffer + 50mM MgCl2 and 100 
µM ATP) supplemented with 10 µCi 32P-labelled ATP (Amersham) and 0.250 µg non-
phosphorylated GST-ERK2 (Upstate) per reaction.  The kinase reaction was maintained at 37 ºC 
for 25 minutes and terminated by pelleting the Sepharose beads, and adding 10 µL 6x Laemmli 
Buffer to the individual supernatant fractions, which were then placed on ice.  After boiling for 
10 minutes, 20 µl of each of the samples was loaded onto a 10 % polyacrylamide gel and 
electrophoresed at 150 V for 1 hour.  Autoradiographic exposures of the gels were performed for 
4-12 hours at -80ºC. 
Indirect Immunofluorescence   Cortical cells were plated directly onto 0.05 mg/mL poly-lysine 
coated 12-well tissue culture plates.  Cells were treated with or without 5 µM cytosine-
arabinoside (Ara-C) at DIV2.  On DIV4, cells were washed twice with PBS, fixed in 4% 
paraformaldehyde for 18 minutes, permeabilized with 0.1% Triton X-100 for 10 minutes, and 
blocked for 1 hour with PBS supplemented with 10% goat serum (Invitrogen) at room 
temperature.  The fixed cells were incubated with anti-GFAP (1:500) in PBS with 10% goat 
serum overnight at 4˚C and washed three times with PBS before incubation with a fluorescent-
labelled secondary antibody (1:1000 anti-rabbit IgG conjugated to Alexa Fluor 488; Molecular 
Probes, Eugene, OR) and the nuclear stain DAPI (1:1000).  Images were viewed with a Zeiss 
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 Axiophot inverted fluorescence microscope, and the number of glial cells was counted in three 
random fields and calculated as a percentage of total cells. 
Detection of intracellular ROS   Intracellular ROS was measured as previously described (Hsieh 
et al., 1998).  Primary cortical cells were treated as described, and the dye DCFH-DA (50 µM) 
(Molecular Probes, Eugene, OR) was added for 1 hour to establish a stable intracellular level of 
the probe.  DCFH-DA is taken up by cells, where it is converted by esterases to DCFH, and is, in 
turn, oxidized to DCF in the presence of ROS.  The extent of increases in the DCF fluorescence 
signal is therefore correlated with increases in intracellular oxidative stress.  After one hour, cells 
were washed with HBSS, scraped from their plates, and measured for DCF fluorescence 
intensity (excitation 475, emission 525) in a fluorometer (Wallac Victor2, Perkin Elmer, 
Wellesley, MA).  Cell counts from each sample were used to normalize the DCF signal intensity.  
A 500 µM dose of H2O2 (2 hours) was used as a positive control for the detection of oxidative 
stress.  Data were expressed as the fold-change in DCF signal intensity compared to control cells 
within each independent experiment.   
 
Statistics  One-way ANOVA was performed with Bonferroni’s post-hoc correction for multiple 
comparisons.  P values less than 0.05 were taken to be significant. 
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 4.4. RESULTS 
4.4.1. LY294002 Protects Primary Mixed Cortical Cultures from Glutamate-Induced 
Oxidative Toxicity   
 
Primary immature cortical neuronal cultures (DIV 3-4) undergo an apoptotic cell death 
within 24 hours of exposure to 5 mM glutamate (Ratan et al., 1994).  This glutamate-induced 
oxidative toxicity has been used extensively as a model for oxidative stress in neurons (Murphy 
et al., 1990; Ratan et al., 1994; Li et al., 1997; Stanciu et al., 2000).  We have previously 
determined that glutamate-induced oxidative toxicity can be abrogated in cortical cultures by 
administration of the MEK inhibitor U0126 (10 µM) (Stanciu et al., 2000).  Mixed cultures of 
immature cortical cells (DIV3) were either left untreated, treated with 5 mM glutamate, or 
treated with 5 mM glutamate administered with 10 µM U0126 for 24 hours.  As shown in 
Figures 2A and 2B, U0126 protects these cells from glutamate-induced oxidative toxicity.  
Treatment with U0126 alone did not affect cell viability or morphology (data not shown).  To 
examine the role of PI3K-Akt in glutamate-induced oxidative toxicity, we used various doses of 
the specific PI3K inhibitor, LY294002 (Ki = 1.4 µM).  Because the PI3K-Akt signaling pathway 
has been associated so reliably with neuroprotection in a wide variety of neurotoxicity models, 
we anticipated that the administration of LY294002 would not be able to prevent glutamate-
induced oxidative toxicity.  Surprisingly, LY294002 conferred significant neuroprotection 
against glutamate-induced oxidative toxicity at doses ranging from 10 µM to 40µM (Figure 2B, 
20 µM and 40 µM doses shown).   
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Figure 2 Representative phase-contrast images (400x magnification) demonstrating 
glutamate-induced oxidative toxicity in primary cortical neurons and neuroprotection via PI3K 
or MEK-1 inhibition.  A, Immature primary cortical cultures (DIV3) were either left untreated or 
treated with 5 mM glutamate for 24 hours.  B, Cultures were treated with glutamate plus either 
20 µM LY294002, 40 µM LY294002, or 10 µM U0126.  Both compounds led to significant 
neuroprotection from glutamate-induced oxidative toxicity, as assessed 24 hours after the 
initiation of glutamate treatment. 
 
 
 
5 mM Glutamate + 
20 µM LY294002 Control 
5 mM Glutamate 
5 mM Glutamate + 
40 µM LY294002 
5 mM Glutamate 
+ 10 µM U0126 
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 To quantify the ability of these inhibitors to abrogate glutamate-induced oxidative 
toxicity, we employed the PI-uptake assay, which utilizes the property of this fluorescent dye to 
be taken up selectively by dying or dead cells, but not by viable cells.  PI uptake has been 
demonstrated in cells ungoing either necrosis or apoptosis and thus does not identify a specific 
cell death mechanism.  Nonetheless, it is a sensitive measure of membrane integrity and is a 
marker of cell health.  PI labeled and unlabeled cells were counted in three fields per 
experimental condition in at least three separate cultures 18 hours after the initial exposure to 
glutamate.  At this time point, cells destined to die have begun to retract their processes, have 
shrunken cell bodies, and display condensed nuclei.  The vast majority of cells treated with 
glutamate display all of these features within 20-24 hours and become detached from the plate 
soon after this time.   Figure 3 demonstrates the dose dependency for the neuroprotective effects 
of LY294002.  Doses of LY294002 ranging from 1 µM to 5 µM did not abrogate glutamate-
induced oxidative toxicity, whereas higher doses (e.g. 10-30 µM) significantly protected cells 
when compared to glutamate treated cultures (p < 0.001).  The administration of 20 µM alone 
did not lead to cell death (Figure 5C), but 40 µM LY294002 alone exhibited some toxicity 
(Figure 3A).  Wortmannin, which inhibits PI3K through a different mechanism than LY294002 
but is much less stable in aqueous solution (Walker et al., 2000), also protected against 
glutamate-induced oxidative toxicity and was not toxic when administered alone (Figure 3C).          
 To examine whether a subthreshold 0.5 µM U0126 dose (i.e., a dose that did not by itself 
protect neurons from glutamate-induced oxidative toxicity; Figure 3B) could potentiate the 
neuroprotective effect of LY294002, 0.5 µM U0126 and increasing doses of LY294002 (1 µM – 
40 µM) were co-administered to cortical cultures with 5 mM glutamate.  In the presence of this 
subthreshold dose of U0126, the minimum dose of LY294002 that was found to be significantly 
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 neuroprotective was 5 µM, half the dose than that found to be effective in the absense of U0126 
(Figure 3B).  These results suggest that some crosstalk between the PI3K-Akt and MEK-ERK 
pathways may be operating in these neurons undergoing oxidative stress.  
 The manner in which LY294002 was administered was critical for its neuroprotective 
effect.  For example, one bolus of inhibitor (30 µM) given at the initiation of glutamate treatment 
led to protection from toxicity (Figure 3A).  However, administering one 20 µM dose of 
LY294002 at the initiation of glutamate treatment and a subsequent 20 µM dose 6 hours later 
completely abolished the neuroprotective effect of the drug (Figure 3A).  This phenomenon was 
also observed for an analagous 30 µM - 30 µM LY294002 dosing schedule (Figure 3A).  The 
administration of two 20 µM doses of LY294002 six hours apart by itself was not toxic to the 
cells (Figure 5C).  Furthermore, delaying the administration of LY294002 by 6 hours after the 
addition of glutamate abolished any protective effect of the compound (Figure 3C).  This 
evidence would suggest that some critical PI3K-dependent event occurs within 6 hours, but not 
later, and that this event is necessary for glutamate-induced oxidative toxicity.   
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Figure 3  The neuroprotective effect of LY294002 is dose-dependent, and concurrent 
inhibition of both MEK and PI3K can potentiate neuroprotection from glutamate-induced 
oxidative toxicity.  A, Primary immature cortical cultures (DIV 3) were treated with 5 mM 
glutamate and increasing single doses of LY294002 (1 µM to 40 µM), two doses (20 µM or 30 
µM) of LY294002 each administered six hours apart (i.e. one with the initial treatment of 
glutamate and another six hours later), 10 µM U0126, or 40 µM LY294002 alone.  Eighteen 
hours after initial treatment, cells were incubated for 10 minutes with propidium iodide (PI) to 
visualize dead or dying PI-positive cells using an inverted fluorescence microscope equipped 
with phase-contrast optics.  Both PI-positive and PI-negative cells were counted, and the 
percentage of PI-positive cells was calculated for three random fields in at least three separate 
cultures.  LY294002 exihibited significant protection at doses of 10 µM or higher, while giving 
two separate doses of LY294002 abrogated its protective effect.  All comparisons were made 
relative to glutamate treatment alone.  B, Subthreshold doses of U0126 can potentiate the 
protective effect of LY294002.  A subthreshold dose of U0126 (0.5 µM) alone, or with 
increasing doses of LY294002, was administered at the initiation of 5 mM glutamate treatment.  
While 0.5 µM U0126 did not significantly protect cultures from glutamate toxicity, the lowest 
significantly neuroprotective dose of LY294002 was 50% lower (i.e. 5 µM vs. 10 µM) in the 
presense of 0.5 µM U0126.  All comparisons were made relative to glutamate treatment alone.  
C, Wortmannin Protects Primary Cortical Cultures from Oxidative Toxicity.  Either a 100nM or 
200nM dose of wortmannin was given alone or concurrently with glutamate, and toxicity was 
measured using PI.  Both doses significantly protect neurons from cell death, and neither is toxic 
alone.  Interestingly, a 6 hour delay in the administration of LY294002 (30 µM) abolishes its 
ability to protect neurons from oxidative toxicity. All comparisons were made relative to 
glutamate treatment alone. * = p<0.05 and *** = p<0.001; U=U0126, LY=LY294002, 
W=Wortmannin. 
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 4.4.2. Both LY294002 and Wortmannin Only Transiently Inhibit PI3K in Mixed 
Cortical Cultures   
 
 To confirm that LY294002 and wortmannin indeed inhibited the PI3K-Akt pathway in 
our cultures, we administered the drugs for various amounts of time and monitored levels of 
phosphorylated Akt as an output measure of PI3K activity.  As shown in Figure 4A, in primary 
immature mixed cortical cultures, a single LY294002 treatment (20 µM) only transiently 
inhibited Akt phosphorylation.  This dose had conferred significant neuroprotection from 
glutamate-induced oxidative toxicity (Figure 1B, Figure 3A).  This was similarly observed in 
wortmannin-treated cultures (Figure 4B).  Consistently, phosphorylated Akt returned to baseline 
levels within about 6 hours after the initial administration of both drugs.  Thus, LY294002 and 
wortmannin administration to mixed primary cortical cultures both inhibit PI3K transiently and 
have no long term effect (i.e., beyond 6 hours) on the PI3K-Akt pathway.  Figure 3 shows 
representative Western blots from at least 3 independent experiments.   
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Figure 4  Both LY294002 and wortmannin only transiently down-regulate phosphorylated 
Akt in primary immature cortical cultures.  Representative Western Blot (n=3) performed using 
whole cell lysate protein (20 µg per lane) from cultures treated for 1, 2, 3, 6, or 10 hours with 
LY294002 (20µM) (A), wortmannin (100nM) (B) or from untreated control cultures.  Blots were 
probed with anti-phospho-Akt specific antibodies, stripped, and reprobed with anti-total Akt 
antibodies.  LY = LY294002, W=Wortmannin. 
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 4.4.3. LY294002 Is Sequestered or Metabolized by Glial Cells in Mixed Cortical 
Cultures  
 
 Because LY294002 is known to be stable in aqueous solution, the apparent loss after 6 
hours of its efficacy to inhibit PI3K action on one of its downstream targets (i.e., Akt) would be 
consistent with metabolism or sequestration of the compound.  To further explore this 
phenomenon of transient PI3K inhibition in our culture system, we asked whether the presence 
of glial elements in the system was responsible for this apparent LY294002 inactivation.  Our 
cultures typically contain about 20-25% GFAP-positive cells at DIV 3-4, as determined by 
immmunocytochemical staining (20.3% +/- 7.2 SEM).  The anti-mitotic agent cytosine 
arabinoside (Ara-C) was added to the mixed cultures, and LY294002 administered 2 days later, 
after the vast majority of glial cells were eliminated.  The efficacy of Ara-C in eliminating 
GFAP-positive cells was verified by immunocytochemistry (i.e., fewer than 1% of cells were 
GFAP-positive).  As shown in Figure 5A, a single administration of 20 µM LY294002 to these 
enriched neuronal cultures is very effective in inhibiting PI3K activity for a prolonged period of 
time (i.e., 10 hours).  This implies that the transient inhibition of PI3K activity in mixed cultures 
given a single dose of LY294002 may be due to glial metabolism or sequestration of the drug.  
To further test this hypothesis, we administered a lower dose of LY294002 (10 µM) to the 
hippocampal cell line, HT22.  These cultures are devoid of glial cells, and therefore we expected 
LY294002 to have a prolonged effect in inhibiting PI3K.  Indeed, as shown in Figure 5B, a 
single dose of LY294002 (10 µM) was sufficient to inhibit PI3K for extended periods of time.  
Furthermore, low doses of LY294002 are toxic to HT22 cells (data not shown), which confirms 
that prolonged maintenance of PI3K activity plays an important role in neuronal cell survival.     
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  To further confirm that the maintenance of PI3K activity is important to the survival of 
primary cortical neurons, we measured the viability of cells in Ara-C-treated, neuron-enriched 
cultures following treatment with LY294002.  As shown in Figure 5C, 20µM LY294002, 
administered in one single dose, or two doses six hours apart, to mixed cortical cultures shows no 
toxic effect.  However, in neuron-enriched cultures, single doses of LY294002 ranging from 10 
µM to 30 µM showed significant neurotoxicity (Figure 5C, p < 0.001).  Thus prolonged PI3K 
inhibition alone is sufficient to undermine cell survival in our cultures.     
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Figure 5 LY294002 is metabolized or sequestered by glial cells in mixed cortical cultures.  
Western Blots were performed using whole cell lysate protein (20 µg per lane) from neuron-
enriched cultures and HT22 cells (a hippocampal cell line).  Blots were probed with anti-
phospho-Akt specific antibodies, stripped, and reprobed with anti-total Akt antibodies.  A, The 
transient inhibition of PI3K (as assessed by phosphorylated Akt) observed in mixed cortical 
cultures is not seen in neuron-enriched cultures.  Neuron-enriched cultures were obtained by 
treating mixed cultures (DIV 2) with 5 µM cytosine-β-D-arabinofuranoside (Ara-C) for two 
days.  These cultures were then treated with a 20 µM dose of LY294002 for either one hour or 
ten hours, and whole cell lysate protein was collected for Western Blot analysis.  B, LY294002-
induced PI3K inhibition is prolonged in HT22 cells.  HT22 cells were treated with 10 µM 
LY294002 for 1, 2, 4, 6, or 9 hours, and whole cell lysates were collected for Western Blot 
analysis.  C, The toxicity of various doses of LY294002 in mixed- and neuron-enriched cortical 
cultures was assessed by PI-uptake (see Figure 2) eighteen hours after treatment.  Neither 20 µM 
LY294002 administered in one single dose or in two repeated doses six hours apart were toxic to 
mixed-cortical cultures.  However, single doses of LY294002 (10 µM – 30 µM) were 
significantly toxic to neuron-enriched cultures.  *** = p < 0.001; LY=LY294002; Ara-C = 
neuron-enriched cultures. 
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 4.4.4. Transient, Early PI3K Inhibition Prevents the Development of a Delayed ERK 
Activation   
 
We have previously determined that glutamate-induced oxidative toxicity is associated with 
a delayed chronic activation of ERK1/2 and that this activation is necessary for neuronal cell 
death (Stanciu et al., 2000) (Figures 2 and 3A).  In cortical cultures, we typically observe this 
delayed activation 10 hours or more after the initiation of glutamate treatment, which correlates 
with the times of increasing oxidative stress in these cells (Li et al., 1997) (Figure 8).  We 
therefore asked whether LY294002 or wortmannin, both of which protect these cultures from 
glutamate-induced oxidative toxicity (Figures 2 and 3), interfere with the development of this 
delayed ERK1/2 activation.  As shown in Figure 6A, 30 µM LY294002, a dose that significantly 
protected cortical neurons, is effective in preventing the delayed activation of ERK1/2.  
Furthermore, treatment with either 100 nM or 200 nM wortmannin showed attenuation of the 
ERK activation measured 10 hours after glutamate administration (Figure 6B).  Interestingly, a 6 
hour delay in the administration of LY294002 after glutamate, a protocol that failed to protect 
cortical neurons from oxidative toxicity (Figure 3C), abolished the ability of the compound to 
prevent the later ERK activation seen during oxidative toxicity (data not shown).  Thus, only an 
early, transient inhibition of PI3K activity in immature cortical neurons can inhibit the delayed 
activation of ERK that accompanies glutamate-induced oxidative stress.  
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 4.4.5. PI3K Inhibition Prevents the Delayed Activation of MEK-1   
 
 PI3K has been found to exert either a stimulatory or an inhibitory effect on ERK 
activation depending, in part, upon the identity and strength of the applied extracellular stimulus 
(Duckworth and Cantley, 1997; Wennstrom and Downward, 1999; Moelling et al., 2002).  In 
cases in which PI3K is necessary for ERK activation, B-Raf appears to be a major conversion 
point for these two pathways, especially in neurons (York et al., 2000).  Because MEK-1 is the 
major target of all Raf isoforms, we used an immunoprecipitation (IP)-kinase assay to monitor 
changes in MEK-1 activity in extracts prepared from primary neurons treated with glutamate in 
the presence or absence of LY294002.  In this way, we could determine whether PI3K acted at 
the level of ERK or on upstream kinases, such as Raf / MEK-1, during the development of the 
PI3K-dependent, delayed ERK activation.  Previous studies have implicated PI3K activity in 
MEK-independent ERK activation.  Interestingly, in one study of PDGF stimulated fibroblasts, 
ERK activation was shown to follow a biphasic pattern with a brief rise and fall in activity 
followed by sustained activity (Grammer and Blenis, 1997).  The early rise in ERK activity was 
MEK-dependent, but the delayed, sustained activation was PI3K dependent and MEK-
independent (Grammer and Blenis, 1997).  This would imply that PI3K dependent signaling 
events can potentially lead to direct ERK activation.   
 As is shown in Figure 7, glutamate-induced oxidative toxicity in primary immature 
cortical cells leads to the delayed recruitment of active MEK-1 at 10 hours, which is consistent 
with the observed onset of ERK activation.  This result is not surprising given that the MEK-1 
inhibitor U0126 was previously shown to prevent the development of ERK activation at this time 
point (Stanciu et al., 2000).  However, administration of LY294002 at the initiation of glutamate 
treatment prevented the recruitment of MEK-1 activity at 10 hours, showing that the late 
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 recruitment of MEK-1 is dependent upon early, but not late PI3K activity (Figure 7).  Thus, 
PI3K activity must affect the ERK pathway at the level of MEK-1 or upstream of MEK-1 during 
glutamate-induced oxidative toxicity, formally eliminating the possibility that PI3K activity 
influences ERK phosphorylation independent of MEK-1.   
 
-- -- +**-- -- -- -- -- --U (10 µM) 
-- -- -- -- -- + + --+LY (30 µM) 
Glutamate -- -- + ++ + + + +
11 66 10 10 10-- --Time (hrs) 
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GST-ERK2 
Figure 7 PI3K inhibition prevents the delayed recruitment of MEK-1 activity in glutamate-
treated immature primary cortical cultures.  MEK-1 immunocomplexes were isolated using 
Protein-A Sepharose beads, and MEK-1 activity was determined via the incorporation of 32P into 
purified, unphosphorylated GST-ERK2 protein (see Methods).  MEK-1 activity was strongly 
induced at 10 hours, and early LY294002 administration abrogated this induction.  Image shown 
is representative of 3 independent experiments.  * = negative control: control lysates were 
immunocomplexed with a non-specific FITC conjugated rabbit anti-sheep antibody; ** = 
negative control: the 10 hour glutamate sample was processed as specified, except 10 µM U0126 
was added into the second Lysis Buffer wash and during the kinase reaction. 
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 4.4.6. Neither PI3K Inhibition nor MEK Inhibition Prevents Oxidative Stress in 
Primary Mixed Cortical Cultures    
 
To test the hypothesis that the protective effects of PI3K inhibition or MEK inhibition may 
be due to the prevention of oxidative stress in our cultures, we measured ROS production using 
the dye DCF.  As can be seen in Figure 8, a significant increase in DCF fluorescence intensity is 
seen 10 hours, but not 4 hours, after the administration of glutamate.  A high dose of H2O2 was 
used as a positive control in the assay.  Interestingly, neither LY294002 (30µM) nor U0126 
(10µM) significantly affected the extent of oxidative stress measured 10 hours after glutamate 
administration.  This implies that the loss of ERK activation 10 hours after glutamate treatment 
(via PI3K inhibition or direct MEK inhibition) can uncouple cells from oxidative toxicity despite 
the ongoing presence of oxidative stress.  Further experiments will be needed to determine if 
cells eventually recover anti-oxidant control systems and reduce oxidative stress in the presence 
of U0126 or LY294002.  This may explain the longevity of our cultures in during ERK 
inhibition in the long term.  Furthermore, the mechanism by which continued oxidative stress 
during MEK-inhibition fails to lead to the activation of other pathways is currently unknown.  It 
is possible that ERK activity is needed for the recruitment of these potential alternative signaling 
events.   
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Figure 8 Neither PI3K nor MEK inhibition prevents the development of glutamate-induced 
oxidative stress in immature primary cortical cultures.  Cells were treated with glutamate for 
either 4 hours or 10 hours, or 10 hours with glutamate with either LY294002 (30 µM) or U0126 
(10 µM), or with 500 µM H2O2 for 2 hours, or left untreated.  One hour prior to analysis, cells 
were loaded with 50 µM DCFH-DA.  Cells were washed in HBSS, collected, and tested for the 
intensity of DCF fluorescence (Excitation 475, Emission 525).  DCF intensities were adjusted to 
cell counts, and the signal was compared to untreated cells (fold-change).  Data presented 
represents the average of 4 independent experiments.  * = p < 0.05; *** = p < 0.001 
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 4.5. DISCUSSION 
 
 The PI3K-Akt pathway is well recognized for its ability to mediate neuronal protection 
from a wide range of toxic insults and conditions (Brunet et al., 2001).  In many cases, inhibition 
of PI3K (e.g., wortmannin, LY294002) has been instrumental in establishing the neuroprotective 
action of this pathway (Zheng et al., 2002).  However, we report here that transient inhibition of 
the PI3K-Akt pathway can protect primary neurons from oxidative toxicity.  Thus, PI3K activity 
may be required for some initial steps of a cell death program that unfolds when neurons are 
subjected to oxidative stress.  To our knowledge, this is the first demonstrated example of PI3K 
activity associated with cell death.  Importantly, a transient “window” of PI3K inhibition in 
mixed cortical cultures exposed to LY294002 or wortmannin enabled us to distinguish between 
the short-term and long-term requirements for PI3K activity in this neurotoxicity model.  
Transient PI3K inhibition is apparently insufficient to undermine the long-term pro-survival 
function of this pathway.  Since neuron-enriched cultures of the same age treated with 
LY294002 do not exhibit a transient inhibition of PI3K activity, it seems likely that glial cells in 
our cultures (~20-25%) are responsible for the metabolism, inactivation, or sequestration of 
LY294002.  Although we have not detected appreciable inactivation of LY294002 in enriched, 
mature astrocyte cultures (data not shown), there are other glial cell types in our mixed cultures 
that could exhibit this activity.   
 Our results are consistent with the wealth of data supporting a neuroprotective role for the 
PI3K pathway, including in an established cell culture model of oxidative toxicity (i.e. HT22 
cells).  We are able in our mixed cultures to generate prolonged inhibition of PI3K by simply 
administering LY294002 in two boluses 6 hours apart.  In the case in which PI3K activity was 
inhibited for prolonged periods of time (i.e., up to 12 hours), the neuroprotective effects of 
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 LY294002 were abrogated.  Furthermore, in neuron-enriched cultures, a single bolus of 
LY294002 was toxic due to prolonged inhibition of the PI3K-Akt pathway (Figure 5C).  This 
finding is consonant with recent data showing that a single 20 µM dose of LY294002 is toxic to 
neuron-enriched primary hippocampal cultures (Luo et al., 2003).   
 Transient inhibition of the PI3K-Akt pathway does not affect neuronal survival in other 
models in which prolonged inhibition would be predicted to lead to cellular demise.  For 
example, infusion of the PI3K inhibitor wortmannin, an unstable compound in aqueous solution, 
into the amygdala of rats impaired their ability to learn in a fear-conditioning paradigm soon 
after the administration of the drug, but did not affect their ability to be effectively re-trained on 
the same paradigm several days later (Lin et al., 2001).  This implies that the effects of 
wortmannin in vivo are reversible and do not result in neuronal cell death, at least not in the 
amygdala.  Similarly, LY294002 has been used in vivo in models of transient focal cerebral 
ischemia- or seizure-induced neuronal toxicity, and in these studies LY294002 alone did not lead 
to increased neuronal cell death in the hippocampus or the caudate / putamen (Noshita et al., 
2001; Henshall et al., 2002), presumably due to the surrounding glia.  Our demonstration of 
transient PI3K inhibition by LY294002 in mixed neuronal / glial cultures provides strong support 
for the notion that metabolism, inactivation, or sequestration of LY294002 can have functional 
consequences for neuronal cell responses to a cell death-inducing stimulus.  This finding would 
be of great interest in the development of therapeutic uses of these compounds in vivo, where 
surrounding glial elements would likely alter the pharmacodynamics of these drugs in the central 
nervous system.  
 We have previously determined that glutamate-induced oxidative toxicity is associated 
with the development of a delayed activation of ERK1/2, and that the MEK inhibitor prevents 
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 this activation and is significantly neuroprotective (Stanciu et al., 2000; Stanciu et al., 2002).  
Interestingly, the ability of transient PI3K inhibition to protect these cultures is associated with 
an abrogation of delayed MEK-1 activation (Figure 7) and ERK1/2 phosphorylation (Figure 6).  
This further establishes ERK1/2 activation in this model as a requisite event for eventual cellular 
demise.  In addition, because of the temporal disparity between the period of PI3K inhibition and 
the regulation of ERK1/2 activity, we can place PI3K activation upstream of the course of events 
that lead to MEK-1 and ERK1/2 activation.  Furthermore, the fact that neither PI3K nor MEK 
inhibition blocks oxidative stress implies that somehow PI3K inhibition can uncouple ERK 
activation from oxidative stress and that oxidative stress is not dependent upon ERK activation in 
this model (Figure 8).   
 Cross-talk between the PI3K-Akt and Raf-MEK-ERK pathways has been demonstrated 
in an increasingly diverse set of circumstances and in different cell types.  Although initially this 
link was reported to be involved in the signaling of G-protein coupled receptors (Hawes et al., 
1996; Lopez-Ilasaca et al., 1997), PI3K activity can be necessary for the recruitment of the ERK 
pathway in signaling events associated with other types of receptors as well.  For example, PI3K 
activity is required for in vitro ERK activation in AMPA and NMDA receptor-mediated 
signaling events in striatal cultures (Perkinton et al., 1999; Perkinton et al., 2002) and for NGF-
induced sustained activation of ERK during PC12 differentiation (York et al., 2000).  
Furthermore, PI3K activation was shown to occur upstream of ERK activation in a rat model of 
associative learning (Lin et al., 2001).  Of great interest is the recent finding that PI3K positively 
contributes to the activation of ERK1/2 in cortical cultures exposed to oxidative stress induced 
by hydrogen peroxide (Crossthwaite et al., 2002).  Thus, there appears to exist a mechanism for 
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 functional coupling of the PI3K and ERK pathways in neurons, with the potential for PI3K to act 
as a required upstream activator.  
 Contradictory effects of PI3K on the ERK pathway have been noted and were initially 
attributed to cell-type specific signaling events that reflected a wide variety of direct and indirect 
interactions between the two pathways (Hawes et al., 1996; Lopez-Ilasaca et al., 1997; 
Zimmermann and Moelling, 1999).  However, recent reports showing opposing effects of PI3K 
on ERK activation within a single cell type in response to one signal reveal the importance of 
signal intensity in dictating the eventual outcome of PI3K/ERK cross-talk (Duckworth and 
Cantley, 1997; Wennstrom and Downward 1999; Moelling et al., 2002).  Furthermore, EGF-
induced ERK activation was found to be PI3K-dependent under conditions under which PI3K 
activity remained near basal levels (Wennstrom and Downward, 1999).  This previously 
described “permissive” effect of the PI3K pathway on ERK activation (Duckworth and Cantley, 
1997; Sutor et al., 1999; Wennstrom and Downward, 1999; Crossthwaite et al., 2002) appears to 
operate in our neuronal cultures, given that increased stimulation of PI3K activity in response to 
glutamate treatment is minimal (data not shown).  However, our neuronal cultures exhibit a 
substantial baseline level of PI3K activity (Figures 4A, 4B and 5A).  Interestingly, our results are 
unique in that the coupling between PI3K and ERK is restricted to a distinct kinetic phase during 
the progression of an oxidative-stress induced cell death pathway. Thus, inhibition of basal PI3K 
activity (as assessed by levels of phosphorylated Akt) at early times following the initiation of 
glutamate treatment (i.e., within 4-6 hours) impacts ERK activation that is only apparent 
following an additional 4-6 hours.  
 We consider the observed coupling in our primary neuron cultures to reflect a permissive 
effect of PI3K on ERK activation. Glutamate-induced oxidative toxicity in immature neurons 
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 and in HT22 cells is driven by a delayed rise in intracellular ROS and Ca2+ (Tan et al., 1998).  
The rapid burst and accumulation of ROS and Ca2+ that ultimately results from glutamate 
treatment are likely to be proximal to the terminal execution phases of the cell death program 
that operates in these cells (Tan et al., 1998).  PI3K has been found to influence plasma 
membrane Ca2+ channel activity through activated Akt and thereby contribute to neuronal cell 
survival in response to neuroprotective factors such as IGF-1 (Blair et al., 1999).  Furthermore, a 
VDCC-dependent form of long-term potentiation at hippocampal CA1 region synapses was 
found to require PI3K activity, implying that PI3K activity can directly regulate calcium entry 
into neurons (Sanna et al., 2002).  In addition, PI3K has been demonstrated to be required for the 
activation of voltage-independent Ca2+ channels in a CHO cell system (Kawanabe et al., 2002) 
and VDCCs in vascular smooth muscle cells (Seki et al., 1999), non-selective cation channels 
(NSCCs) (Kawanabe et al., 2003), and for Ca2+ release from intracellular SOCCs (Kawanabe et 
al., 2003).  Furthermore, there is increasing evidence showing that PI3K activity is not only 
necessary for increases in intracellular Ca2+ but that this increase in Ca2+ is necessary for ERK 
activation (Kansra et al., 2001).  Interestingly, PI3K-dependent increases in intracellular Ca2+ 
have been shown to be dissociated from increases in phosphorylated Akt and may represent a 
point of divergence between action of PI3K on the Akt versus the ERK pathway (Kansra et al., 
2001; Kawanabe et al., 2003).  This is consistent with our findings that Akt activation (above 
baseline) is minimal during the development of glutamate-induced oxidative toxicity (data not 
shown).  Thus, it is tempting to speculate that the permissive effects of PI3K on ERK-dependent 
cell death in oxidatively stressed primary neurons might be due to effects of basal PI3K activity 
on either plasma membrane Ca2+ channels, or intracellular store-operated channels.  ROS 
generated by the mitochondria contribute to Ca2+ influx and accumulation in glutamate-treated 
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 HT22 cells and primary cortical neurons (Li et al., 1997; Tan et al., 1998), and a Ca2+ channel 
response to ROS that requires some direct or indirect priming action of the PI3K pathway may 
very well be the link between the PI3K and ERK pathways in our system.  Previous studies have 
demonstrated that HT22 cells and primary cortical neurons are protected from oxidative toxicity 
by blocking plasma membrane Ca2+ channels (i.e., with CoCl2) or by inhibiting Ca2+-uptake into 
the mitochondria (i.e., with ruthenium red) (Tan et al., 1998).  Thus PI3K inhibition may protect 
neurons from oxidative toxicity by altering the activity of Ca2+ channels and transporters.         
 The identification of multiple intracellular signaling pathways that operate to promote or 
limit neuronal cell death and the delineation of various levels of cross-talk between these 
pathways both present unique challenges to the development of pharmacological neuroprotective 
therapies.  Our results suggest that depending upon the nature and identity of the coupled signal 
transduction pathways, a temporal window may exist that allows for the transient inhibition of a 
specific signal transduction pathway. Thus, rapid metabolism or sequestration of drugs targeted 
to specific signaling pathways may prove beneficial particularly in cases where unique coupling 
between signal transduction pathways occurs at distinct kinetic phases of a progressing cell death 
program.  
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 5. CHAPTER 2:  Reversible oxidation of ERK-directed protein phosphatases drives 
oxidative toxicity in neurons 
 
5.1. SUMMARY 
 Oxidative stress links diverse neuropathological conditions that include stroke, 
Parkinson's Disease, and Alzheimer's Disease, and has been modeled in vitro with various 
paradigms that lead to neuronal cell death following the increased accumulation of reactive 
oxygen species (ROS).  For example, immortalized neurons and immature primary cortical 
neurons undergo cell death in response to depletion of the anti-oxidant glutathione, which can be 
elicited by administration of glutamate at high concentrations.  We have previously demonstrated 
that this glutamate-induced oxidative toxicity requires activation of the mitogen-activated protein 
kinase member ERK1/2, but the mechanisms by which this activation takes place in oxidatively 
stressed neurons are still not fully known.  In this study, we demonstrate that during oxidative 
stress, ERK-directed phosphatases of the serine/theonine- and tyrosine-directed classes are 
selectively and reversibly inhibited via a mechanism that is dependent upon the oxidation of 
cysteine thiols.   
 Furthermore, the impact of ERK-directed phosphtatases on ERK1/2 activation and 
oxidative toxicity in neurons was tested in a neuronal cell line and in primary cortical cultures.  
Overexpression of the highly ERK-specific phosphatase MKP3 and its catalytic mutant MKP3 
C293S were neuroprotective in transiently transfected HT22 cells and primary neurons.   The 
neuroprotective effect of the MKP3 C293S mutant, which enhances ERK1/2 phosphorylation but 
blocks its nuclear translocation, demonstrates the necessity for active ERK1/2 nuclear 
localization for oxidative toxicity in neurons.  Together, these data implicate the inhibition of 
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 endogenous ERK-directed phosphatases as a mechanism that leads to aberrant ERK1/2 
activation and nuclear accumulation during oxidative toxicity in neurons.   
 
5.2. INTRODUCTION  
  Oxidative stress is a common feature of a diverse range of neuropathological conditions, 
including stroke, Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis 
(Coyle and Puttfarken, 1993; Mattson et al., 2001).  Glutamate-induced oxidative toxicity 
provides an excellent model for studying the effects of oxidative stress in immortalized neurons 
and in primary neuronal cultures (Murphy et al., 1990; Ratan et al., 1994; Li et al., 1997).  In this 
model, inhibition of a glutamate/cystine antiporter, known as system xc-, leads to decreased 
accumulation of intracellular free cysteine, a necessary precursor of glutathione, and to eventual 
glutathione depletion.  As a result, reactive oxygen species (ROS) accumulate and activate 
cellular signaling events that contribute to neuronal cell death.  The extent to which system xc- is 
involved in adult neurons in vivo is not fully known, but studies have demonstrated that this 
amino acid antiporter is widely expressed in the adult nervous system.  However, the system is 
expressed primarily in the periventricular areas of the adult mouse brain and in the meninges 
rather than in major nuclei or the cortex (Sato et al., 2002).  Thus in the adult brain, this system 
may function more to maintain the redox state in the CSF (i.e., by regulating the cysteine/cystine 
ratio) than to maintain neuronal levels.  However, in cultured immature primary cortical neurons, 
this system is clearly expressed and is fully functional (Murphy et al., 1990).  We have 
previously shown that oxidative toxicity causes a delayed, sustained activation of ERK1/2 that is 
necessary for neuronal cell death (Stanciu et al., 2000; Stanciu and DeFranco, 2002; Levinthal 
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 and DeFranco, 2004), but the mechanisms by which oxidative stress drives ERK1/2 activation 
have not been fully elucidated.  
 The regulation of ERK1/2 phosphorylation and activation reflects a subtle balance 
between ERK-directed kinase and phosphatase activity.  A diverse range of phosphatases 
directed against phospho-serine/theonine, phospho-tyrosine, or both have been identified as 
negative regulators of ERK1/2.  PP2A (Silverstein et al., 2002; Kim et al., 2003[2]) and STEP 
(Paul et al., 2003), among numerous others, can function as ERK-directed phosphatases in 
neurons.  Dynamic changes in ERK-directed phosphatase activity can result from several 
mechanisms, including ERK-dependent upregulation of phosphatase expression (Bhalla et al., 
2002), phosphorylation-dependent increases in phosphatase stability (Brondello et al., 1999), and 
protein-protein interaction–dependent activation of phosphatase activity (Camps et al., 1998).  
These events collectively have been shown to function in a negative feedback loop that 
terminates ERK signaling (Bhalla et al., 2002).   
 Recently, the role of oxidative stress in the regulation of phosphatase activity has 
received much attention (Meng et al., 2002; Leslie et al., 2003; Persson et al., 2004).  Several 
phosphatases have been shown to be redox sensitive and can be either reversibly or irreversibly 
inhibited, depending upon the degree and mechanism of oxidation (Meng et al., 2002; Tonks, 
2003).  Oxidative phosphatase inhibition can impact various cellular signaling pathways and 
accounts for a mechanism now referred to as oxidative signaling.  The extent to which oxidative 
inhibition of phosphatases plays a role in driving signaling events during neurotoxicity remains 
relatively unexplored. 
 We sought to characterize the effect of glutamate-induced oxidative toxicity on ERK-
directed phosphatases in primary neuronal cultures.  In this study, we show that endogenous 
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 ERK-directed phosphatase activity is specifically and reversibly inhibited during oxidative stress 
consistent with a mechanism involving the oxidation of cysteine thiols.  This inhibition of ERK-
directed phosphatases correlates with an increase in phosphorylated ERK levels.  We show that 
this aggregate phosphatase activity is likely comprised of PP2A and a vanadate-sensitive 
component.  The impact of ERK-directed phosphatase activity on oxidative toxicity was revealed 
by the neuroprotective effects of overexpressed MKP3 and its catalytic mutant, MKP3 C293S, in 
both HT22 cells and primary cortical neurons.  Collectively, these data implicate oxidative 
inhibition of ERK-directed phosphatases in neuronal oxidative toxicity induced by glutathione 
depletion.   
 
5.3. EXPERIMENTAL PROCEDURES 
Plasmids  The expression plasmids for MKP3 WT and MKP3 C293S, as well as the parent 
plasmid (pSG5), were kind gifts from Dr. Steven Keyse and Dr. Anne Brunet (Groom et al., 
1996; Dowd et al., 1998; Brunet et al., 1999).  The mitochondria-targeted eYFP expression 
plasmid was a gift from Dr. Ian Reynolds, and the expression plasmid for the Elk-1/GAL4 fusion 
protein, the luciferase reporter, and the constitutive renilla plasmid (all from Strategene, La Jolla, 
CA) were purchased or donated by Dr. Elias Aizenman. 
 
Primary Cortical Cultures   Cortices from embryonic day 17 Spague-Dawley rat fetuses (Hilltop 
Lab Animals, Scottdale, PA) were dissected and manually dissociated by repeated trituration 
using fire-polished glass pipettes in Hanks Balanced Salt Solution (5.4 mM KCl, 0.3 mM 
Na2HPO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 137 mM NaCl, 5.6 mM D-glucose, pH 7.4) 
without Ca2+ or Mg2+ (Invitrogen, Carlsbad, CA) followed by passage through a 40 µm cell 
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 strainer (Becton Dickinson Labware, Franklin Lakes, NJ) to remove clumped cells.  Cells were 
counted and plated on 50 µg/ml poly-D-lysine treated culture plates at a density of ~2.1 x 104 
cells / cm2.  Cell viability was routinely greater than 80% as assessed by uptake of trypan blue 
dye upon plating.  Cultures were maintained for 3-4 days in media (DMEM (Invitrogen), 10% 
FCS (Hyclone, Logan, UT), 10% Ham’s F12 Nutrient Supplement (Invitrogen), 1.9 mM 
glutamine, 24 mM Hepes Buffer, and 4.5 mg/mL glucose) at 37ºC and 5% CO2.  At this time, 
these mixed cortical cultures are predominately neuronal, with approximately 20% GFAP+ 
staining cells (Murphy et al., 1990).   Unless otherwise stated, all chemicals and reagents used 
were purchased from Sigma Chemical Corporation, St. Louis, MO.    
 
Cell Line Culture  HT22 cells, a hippocampal cell line that is sensitive to glutamate-induced 
oxidative toxicity (Li et al., 1997), were maintained in DMEM supplemented with 10% FCS 
(Atlanta Biologicals, Norcross, GA), 100 Units Penicillin, and 100 µg/mL Streptomycin at 37ºC 
and 5% CO2.   
 
Transfections in Primary Cortical Neuronal Cultures   A number of transfection reagents and 
protocols that were tested proved toxic to our primary immature cortical cultures.  However, 
limited toxicity was observed when the 25 kD polyamine polymer poly(ethyleneimine) (PEI) 
was used to form DNA-complexes and to transfect primary neurons (Guerra-Crespo et al., 2003; 
Horbinski, et al., 2001).  In brief, 2 µL of a 100 mM PEI stock solution was added to 250 µL 150 
mM NaCl, while 6.5 µg of DNA was added to 250 µL 150 mM NaCl.  Two µg of a 
mitochondria-targeted enhanced YFP (mt-eYFP) plasmid DNA and 4.5 µg of MKP3 plasmids 
were used per condition.  After 5 min, the two solutions were mixed.  PEI/DNA complexes were 
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 allowed to form for 10 min, and then diluted into 10 mL MEM (Invitrogen).  Conditioned media 
was removed from the primary neuronal cultures and replaced with MEM.  One mL of 
transfection solution was added to each 35 mm well and left to incubate at 37ºC for 1 hr.  The 
transfection media was then removed and replaced with conditioned media for the remainder of 
the experiment.  The transfection efficiency with this method varied between 0.1 – 0.5 %.  
Glutamate treatment was initiated 24 hrs following transfection. 
 
Transfections in HT22 cells   The cationic lipid reagent Lipofectamine 2000 (Invitrogen) was 
used to transiently transfect HT22 cells.  For toxicity experiments, 2 µg of DNA was used per 
well of a 12-well tissue culture plate, in a DNA (µg) / Lipofectamine 2000 (µL) ratio of 1.5.  
Typically, 1 µg of mt-eYFP plasmid DNA and 1 µg of MKP3 plasmid DNA were used for these 
transfections.  For the Elk-1-dependent luciferase expression experiments, ~8 µg total plasmid 
DNA was used for each 60 mm plate (3 µg pSG5, MKP3 WT, or MKP3 C293S, 4 µg Luciferase 
reporter  plasmid [pFR-Luc], 0.12 µg Elk-1/GAL4 fusion expression plasmid [pFC-Elk-
1/GAL4], or the GAL4 DNA binding domain expression plasmid [pFC-GAL4 DBD], and 1.2 µg 
constitutive Renilla expression plasmid [PRK-tk Renilla]), with a DNA/Lipofectamine 2000 
ratio of 1.5.  DNA and Lipofectamine 2000 were diluted in OptiMEM (Invitrogen) for 5 min and 
then combined to allow DNA complexes to form for 20 min.  The transfection solution was 
added to HT22 cells in serum-free DMEM without antibiotics for 5 hr, after which cells were 
returned to normal serum and antibiotic containing media (see above).  Cells were harvested as 
described beginning 16 to 18 hrs following transfection, and luciferase/renilla activity was 
measured (see below).   
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 Elk-1/GAL4 Fusion Protein-Dependent Luciferase Expression   Components of the PathDetect in 
Vivo Signal Transduction Pathway trans-Reporting System (Stratagene, La Jolla, CA) were used 
in order to monitor Elk-1-dependent gene expression in HT22 cells.  Cells were transfected with 
an expression plasmid coding for an Elk-1/GAL4 fusion protein, a reporter plasmid containing 
the luciferase gene under a synthetic promoter containing 5 tandem GAL4 binding sites, and a 
MKP3 expression plasmid.  In this system, luciferase activity is a measure of the extent of Elk-1 
activation.  HT22 cells were co-transfected with the Elk-1 fusion plasmid (pFA2-Elk-1) or its 
negative control containing only GAL4 (pFC2-DBD), the luciferase reporter plasmid (pFR-Luc), 
a constitutive expression plasmid coding for Renilla under control of the CMV promoter (PRK-
tk Renilla), and either the pSG5 empty vector, MKP3 WT, or MKP3 C293S plasmids.  Sixteen 
hr after transfection, HT22 cells were left untreated or treated with glutamate for 7.5 hr.  Cells 
were then harvested and lysed in Lysis Buffer (see below).  Both luciferase activity and renilla 
activity were measured with the Dual-Glo Luciferase Assay System (Promega, Madison, WI) 
using a luminometer (Wallac Victor3, Perkin Elmer Biosciences, Boston, MA).  All luciferase 
signals were normalized to renilla within each sample.         
 
Viability Measurements in Transfected Cells   Primary cortical neuronal cultures (DIV3) display 
cell body shrinkage, process retraction, and nuclear condensation at 18-20 hr following treatment 
with 5 mM glutamate.  After 24 hr, cells begin to detach from the tissue culture plate.  To assess 
cell viability in transfected neurons (i.e. mt-YFP positive cells; see Methods), we treated cells 
with the DNA dye propidium iodide (PI), which is excluded from healthy, intact cells and only 
gains access into cells with a compromised plasma membrane.  Eighteen hours following the 
initiation of all treatments, cultures were incubated for 10 min in media containing a final 
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 concentration of 6.25 µg/mL PI.  Cells were observed under an inverted fluorescence microscope 
equipped with phase contrast optics (Nikon Eclipse TE200), and mt-eYFP positive, PI-labeled 
and unlabeled cells were counted.  The percentage of dually-labeled cells in each well was then 
calculated as a percentage of all transfected cells counted (approximately 50 cells per well).  
Multiple wells were counted for each condition in at least three separate tranfected cultures (total 
cell population at least 250 per condition).   
 HT22 cells become PI-positive beginning 6-7 hr following 5 mM glutamate treatment 
and begin to detach from the culture plate after 9 hr.  We thus assessed toxicity in transfected, 
mt-eYFP-marker positive cells at 7 hr using the PI staining method as described above.  Cells 
were observed under an inverted fluorescence microscope equipped with phase contrast optics 
(Nikon Eclipse TE200), and mt-eYFP positive, PI-labeled and unlabeled cells were counted.  
The percentage of dually-labeled cells in each field was then calculated as a percentage of all 
transfected cells counted (approximately 60 cells per field at 100x), and multiple fields were 
counted for each condition in at least three separate transfected cultures (total cell population at 
least 500 per condition).   
 
Indirect Immunofluorescence   HT22 cells were plated on 12-well tissue culture plates in normal 
media (see above), and then transfected with either the pSG5 parent plasmid, MKP3 WT, or 
MKP3 C293S expression plasmids for 16-18 hr.  Cells were then washed with phosphate-
buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 
7.4), fixed with -20º methanol for 5 min, washed with PBS, permeabilized with PBS containing 
0.1% Triton X-100 for 10 min, and then blocked for 1 hr with PBS supplemented with 3% BSA 
at room temperature.  The fixed cells were then incubated with an anti-c-myc antibody (1:500; 
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 Cell Signaling, Beverly, MA) or an anti-GAL4 DBD antibody (1:500; Sigma) in PBS with 3% 
BSA for 1 hr at room temperature, washed three times with PBS before incubation with a 
fluorescent-labelled secondary antibody (1:1000 anti-mouse IgG conjugated to Alexa Fluor 488; 
Molecular Probes, Eugene, OR) and the nuclear stain Hoescht 33258 (1 µg/ml).  After washing 
stained cells twice with PBS, images were viewed with a Zeiss Axiophot inverted fluoroscence 
microscope coupled to a cooled CCD camera (Leica DC 300F, Bannockburn, IL).   
 
ERK-directed Phosphatase Activity Assay  We modified a non-radioactive method for 
determining ERK-directed phosphatase activity in whole cell lysates (Laakko and Juliano, 2003).  
This method relies on detecting dephosphorylation of a purified, dually phosphorylated His6-
tagged ERK upon incubation with whole cell lysate.  Thus, alterations in ERK-directed 
phosphatase activity within the lysate can be monitored by measuring changes in the 
phosphorylation state of the isolated substrate, as assessed by Western blotting with a phospho-
specific ERK1/2 antibody.  In brief, 150 µg of whole cell lysate (see below) lacking DTT, 
Na3VO4, or NaF, was diluted into a total volume of 250 µL in phosphatase assay buffer (10 mM 
MgCl2, 10 mM Hepes, pH 7.5, and 10 µM of the MEK inhibitor U0126).  Recombinant, 
phosphorylated His6-ERK2 (Biomol, Plymouth Meeting, PA) was added to each sample at 30 
ng/sample, and the reactions were maintained at 37 ºC for 40 min.  As a positive control for 
phosphatase activity, 1200 Units of the dual-specificity phosphatase Lambda Protein 
Phosphastase (λ-PPase, New England BioLabs, Beverly, MA) was included in a separate 
reaction.  Treatment with 50 mM DTT or phosphatase inhibitors was accomplished during a 30-
min incubation on ice, prior to the addition of purified ERK.  Where DTT and inhibitors were 
used, the samples were pre-incubated for 30 min on ice with DTT, followed by a 15 min 
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 incubation with inhibitors.  After 40 min at 37ºC, the reactions were stopped by the addition of 
250 µL wash buffer (8 M Urea, pH 8.6 containing 10 mM imidizole), and 30 µL of Ni2+-
conjugated, magnetic beads (Qiagen, Valencia, CA) were added to each reaction.  After 90 min 
of rocking at 4ºC, the samples were washed twice with wash buffer and once in 300 mM NaCl, 
25 mM Tris, pH 7.5.  The beads were then suspended in NaCl/Tris and Laemmli buffer, boiled 
for 5 min, loaded onto a 10% polyacrylamide gel, transferred to polyvinylidine fluoride (PVDF) 
membranes (Millipore, Bedford, MA), and subjected to Western Blotting to detect 
phosphorylated ERK and total ERK (see below).   
 
JNK-directed Phosphatase Activity Assay   This method was performed exactly as described 
above, except that each sample was incubated with 30 ng of purified, dually-phosphorylated 
His6-tagged JNK-1 protein (Upstate, Waltham, MA), and Western blots were probed with anti-
phospho JNK and total-JNK antibodies.  
 
Western Blot Analysis  Cells were treated as described, scraped and collected into PBS, pelleted 
at 3000 rpm for 5 min, and resuspended in Lysis Buffer (50mM Tris-Cl, pH 7.5, 2mM EDTA, 
100 mM NaCl, 1% NP-40, 100µM Na3VO4, 100 µM NaF, 2mM DTT) supplemented with 5µL 
protease inhibitor cocktail (Sigma) per mL of lysis buffer.  Total extract protein concentrations 
were determined using the Bio-Rad™ reagent.  Equivalent amounts of total protein (either 15 or 
20 µg) were separated by SDS-PAGE on 10% polyacrylamide gels and then transferred to PVDF 
membranes (Millipore, Bedford, MA).  Membranes were blocked with 5% dry milk in PBS / 
0.1% v/v Tween-20 (PBST).  Membranes were then incubated with primary antibodies (anti-
phospho ERK, anti-total ERK, anti-phospho JNK, anti-total JNK, or anti-c-myc, all from Cell 
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 Signaling) overnight at 4ºC with 3% dry milk or 5% BSA, washed 3x 10 min with PBST, and 
then exposed to the appropriate horseradish-peroxidase (HRP)-conjugated secondary antibody 
for one hour at room temperature.  Membranes were again washed 3x 10 min with PBST, and 
immunoreactive bands detected by enhanced chemiluminescence (ECL, Amersham Biosciences, 
Piscataway, NJ) using standard x-ray film (Kodak, Rochester, NY).  Several different exposure 
times were used for each blot to ensure linearity of band intensities.  Densitometry was 
performed using a Personal Densitometer SI (Molecular Dynamics, Amersham Biosciences) 
linked to the ImageQuant 5.2 software (Molecular Dynamics).   
 
Statistics   Comparisons of multiple mean values were accomplished by ANOVA with either 
Tukey's or Bonferroni's post-hoc tests for significance.  Comparisons of two means were 
performed using a paired t-test.  P values less than 0.05 were taken to be significant, and all data 
was analyzed using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego 
California USA).   
 
 
5.4. RESULTS 
5.4.1. ERK-Directed Phosphatase Activity is Specifically Inhibited during Glutamate-
Induced Oxidative Toxicity in Primary Immature Cortical Cultures   
 
 We have previously reported that in primary immature cortical cultures, ERK1/2 
phosphorylation is elevated during oxidative stress generated by glutamate-induced glutathione 
depletion (Stanciu et al., 2000; Levinthal and DeFranco, 2004).  Given the sensitivity of protein 
phosphatases to cellular redox state (Meng et al., 2002), we set out to examine whether ERK-
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 directed phosphatase activity was altered during glutamate-induced oxidative toxicity.  Toward 
this end, we adapted a novel in vitro phosphatase assay that uses whole cell lysates to 
dephosphorylate purified dually-phosphorylated His6-tagged ERK-2 (see Methods).  This assay 
revealed the robust ERK-phosphatase activity of exogenously applied lambda protein 
phosphatase, a non-specific dual-specificity phosphatase that we employed as a positive control.  
Furthermore, the method proved to be quite sensitive in detecting changes in phosphatase 
activity, as the application of well-characterized phosphatase inhibitors were effective in 
inhibiting phosphatase activity in preparations of whole cell lysate (see below).  Though not as 
active as purified λ-phosphatase, whole cell lysates prepared from primary cortical neurons 
possess robust ERK-directed phosphatase activity (Figure 9A, Lane 1).  When extracts were 
prepared from cultures treated with glutamate for 14 hours, a decrease in ERK-directed 
phosphatase activity was revealed (Figure 9A, Lane 6).  Quantification of several independent 
experiments revealed a significant decrease in ERK-phosphatase activity in cultures treated for 
14 hours with glutamate, as reflected in a 5-fold increase (p < 0.01) in the normalized intensity of 
the phosphorylated ERK2 band when compared to untreated cultures (Figure 9B).  Shorter 
treatments with glutamate (i.e., 1 and 6 hours) did not significantly affect ERK-directed 
phosphatase activity in the primary neuron culture extracts (Fig 9A, lanes 4 and 5).  Thus, the 
observed inhibition of ERK-directed phosphatase activity in these extracts coincided with times 
of maximal oxidative stress in which glutathione levels are depleted and ERK phosphorylation is 
increased (Li et al., 1997; Levinthal and DeFranco, 2004).  Interestingly, inhibition of ERK-
directed phosphatase activity could be completely reversed by treatment of the extracts with 50 
mM DTT (Figure 9A, Lane 7), implying that phosphatase function is impaired in oxidatively 
stressed cells due to cysteine oxidation.  The restoration of ERK-phosphatase activity in 
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 oxidatively stressed cells with DTT consistently yielded a level of activity greater than that found 
in untreated cells (e.g., compare lanes 3 and 7, Figure 9A).  Indeed, DTT treatment of lysates 
from primary cortical neuronal cultures not exposed to glutamate led to increased ERK-directed 
phosphatase activity (data not shown).  Thus, a small pool of ERK-phosphatases may be 
normally under tonic, reversible oxidative inhibition in primary neurons, despite intracellular 
conditions that are generally reducing.  Because oxidative toxicity induced by glutamate in these 
primary cultures depends upon the depletion of glutathione, we sought to reverse the effects of 
thiol oxidation-mediated phosphatase inhibition by re-introducing reduced glutathione into 
whole cell lysates from oxidatively stressed cells.  However, glutathione addition to these 
extracts prepared from oxidatively stressed cells did not increase ERK-phosphatase activity (data 
not shown).  Others have observed this phenomenon, as DTT, but not glutathione, can reverse 
oxidation-dependent inhibition of the phosphatase cdc25 (Sohn and Rudolph, 2003).  It is 
unclear whether this reflects an inability of reduced glutathione to gain access to the oxidized 
cysteine moiety in the ERK-directed phosphatases or cofactors due to steric interference, or 
effects of competing oxidized substrates in the extracts.  Future studies will employ a mixture of 
reduced glutathione, NADPH, and glutathione reductase to allow for a sustainable pool of 
reduced glutathione.  This approach may demonstrate that glutathione can indeed reverse 
oxidation-dependent phosphatase inhibition in the whole cell lysates from oxidatively stressed 
cells.     
 To determine the substrate specificity of phosphatase activity affected by oxidative stress, 
we assayed the activity of JNK-directed phosphatases using purified His6-tagged dually 
phosphorylated JNK1 protein in the same primary neuron lysates used to monitor ERK 
dephosphorylation.  As shown in Figure 9C, JNK1-directed phosphatase activity is not 
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 significantly altered during glutamate-induced oxidative toxicity.   Furthermore, the addition of 
50 mM DTT did not enhance JNK-phosphatase activity in the lysates, unlike the restoration of 
ERK-directed phosphatase activity by DTT in the same lysates.  These extracts do contain some 
active JNK-phosphatases, as phosphorylated JNK levels were reduced upon incubation with 
extracts as compared to input (compare lanes 1 and 3, Figure 9C).  To examine the 
phosphorylation state of endogenous JNK1 (p46) and JNK2/3 (p54) in the primary neurons, we 
performed Western Blot analysis using a phospho-specific JNK antibody.  As can be seen in 
Figure 9D, JNK phosphorylation does not change during glutamate-induced oxidative toxicity, 
even during times of increased oxidative stress (i.e. 12-14 hours after the addition of glutamate).  
This finding is consistent with the lack of regulation of JNK-phosphatase activity by oxidative 
stress.  Thus oxidative stress in immature cortical neuron cultures specifically inhibits the 
activity of a subset of phosphatases that act upon specific MAPK members.  Furthermore, the 
selectivity of oxidative inhibition of MAPK-directed phosphatases revealed in the in vitro assay 
correlate with the specificity of MAPK activation in oxidatively stressed neurons.   
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Figure 9 ERK-directed phosphatase activity is specifically inhibited during glutamate-
induced oxidative toxicity in primary immature cortical cultures.  Primary immature cortical 
cultures were left untreated or treated with glutamate for 1, 6, or 14 hours.  Whole cell lysates 
from these samples were utilized in an in vitro ERK-directed phosphatase activity assay (see 
Methods).  ERK-directed phosphatase activity is significantly reduced during oxidative stress 
(i.e. 14 hours following glutamate treatment), and this inhibition is completely reversible with 50 
mM DTT (A).  The results of between four and eight independent experiments were quantified, 
revealing a significant increase in ERK-directed phosphatase inhibition during oxidative stress 
and a significant restoration of this activity with DTT (B).  The effects of oxidative toxicity on 
MAPK-directed phosphatases are specific to ERK, as JNK-directed phosphatase activity is not 
altered by glutamate treatment (n=3) (C).  Furthermore, endogenous JNK phosphorylation is not 
altered by glutamate treatment (n=3) (D).  * = p < 0.05; I = phosphatase assay input; λ = lambda 
phage protein phosphatase (positive control). 
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 5.4.2. ERK-Directed Phosphatase Activity Can be Inhibited by Okadaic Acid and 
Orthovanadate     
 
 In order to ascertain the contribution of tyrosine/dual-specificity versus serine/threonine-
directed phosphatases to ERK dephosphorylation in primary neuron cultures, we utilized two 
inhibitors:  okadaic acid (OA) and sodium orthovanadate.  OA is a well characterized 
serine/threonine directed protein phosphatase inhibitor with a high degree of selectivity at low 
concentrations for PP2A.  Furthermore, a major component of ERK-phosphatase activity in 
neurons is contributed by PP2A (Foley et al., 2004).  As shown in Figure 10A, treatment with 
either 0.1 µM or 1.0 µM OA led to near complete inhibition of ERK-directed phosphatase 
activity in lysates from untreated control cultures (compare lanes 4 and 5 to lane 3, Figure 10A).  
Thus, our in vitro assay confirms the expected contribution of PP2A to ERK-dephosphorylation 
in neurons.    
 Sodium orthovanadate is a potent inhibitor of tyrosine- and dual-specificity phosphatases 
that does not affect serine/threonine-directed phosphatases.  Currently, there are few compounds 
available that inhibit specific tyrosine- or dual-specificity phosphatases, yet orthovanadate 
remains a useful tool to delineate the contribution of these classes of phosphatases to the 
regulation of protein phosphorylation.  To examine the role of tyrosine- and dual-specificity 
phosphatases to the observed phosphatase activity in untreated neuronal cultures, we treated 
lysates from these cells with 1 mM Na3VO4.  As is shown in Figure 10B and 10C, orthovanadate 
significantly inhibited ERK-directed phosphatase activity in lysates from untreated cultures.  
Importantly, the degree of inhibition observed with orthovanadate was less than that observed 
with OA, further confirming the predominant role of PP2A as an ERK-directed phosphatase 
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 activity in neurons.  Nonetheless, tyrosine- and/or dual-specificity phosphatases appear to 
operate in primary neurons as ERK-directed phosphatases.   
 
A OA
--           --           --         0.1          1      
   I            λ           C          C           C 
pERK 
tERK 
1          2           3            4            5 
 
 
 
 
B   --       --       --     VO4
    I        λ      C       C
pERK 
tERK
 1        2        3        4 
 
 
81 
  
 
 
 
C  
Control Control+VO4
0
1
2
3
4
pE
R
K
 / 
tE
R
K
N
or
m
al
iz
ed
 R
at
io
*  
 
 
 
 
 
 
 
Figure 10 ERK-directed phosphatase activity is inhibited by okadaic acid and 
orthovanadate.  The nature and identity of the components of the basal ERK-directed 
phosphatase activity were probed using the phosphatase inhibitors okadaic acid, an inhibitor of 
PP2A, and sodium orthovanadate, a general inhibitor of tyrosine-directed and dual specificity 
phosphatases.  Whole cell lysates from untreated primary immature cortical neurons were 
incubated with vehicle, 0.1 µM or 1 µM okadaic acid, or 1 mM orthovanadate for 30 minutes 
prior to use in the in vitro ERK-directed phosphatase activity assay.  Both doses of okadaic acid 
were sufficient to inhibit activity (A).  Because orthovanadate led to less inhibition of ERK-
directed phosphatase activity than okadaic acid (B,C), it is likely that tyrosine-directed or dual-
specificity phosphatases that contribute to this activity, while PP2A is the major component.  All 
experiments were conducted at least 4 times.  * = p < 0.05  
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5.4.3. The Reversibly Oxidized Pool of ERK-Directed Phosphatase Activity Can be 
Inhibited by Okadaic Acid and Orthovanadate   
 
Having established parameters for pharmacologic inhibition of ERK-directed 
phosphatases in vitro using lysates from control cultures, we next sought to reveal the nature of 
phosphatase activity recovered by DTT treatment of extracts from oxidatively stressed cells.  As 
shown in Figure 11, 0.1 µM Okadaic acid and 1 mM Na3VO4 were both capable of blocking 
ERK-phosphatase activity restored by DTT in lysates from oxidatively-stressed cells (compare 
lanes 6-8 with lane 5).  Thus, the reversibly inhibited pool of ERK-directed phosphatases that we 
have identified in oxidatively stressed neuronal cultures is likely composed of PP2A and 
vanadate-sensitive activities.      
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Figure 11 The reversibly oxidized pool of ERK-directed phosphatase activity is inhibited by 
okadaic acid and orthovanadate.  Whole cell lysates were prepared from primary immature 
cortical neurons that had been left untreated or treated with glutamate for 14 hours.  The lysates 
from glutamate treated cells were incubated with DTT alone (45 minutes), or DTT (30 minutes) 
followed by a 15-min incubation with 0.1 µM or 1 µM okadaic acid, or 1 mM sodium 
orthovanadate, prior to use in the in vitro ERK-directed phosphatase activity assay.  The 
reversible pool of oxidized ERK-directed phosphatases is inhibited by okadaic acid and 
orthovanadate.  Results shown are representative of four independent experiments.     
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 5.4.4. Overexpression of MKP3 WT and MKP3 C293S significantly alter ERK 
Phosphorylation and Translocation in HT22 Cells    
 
If reversible oxidation of ERK-directed phosphatases such as PP2A or some necessary 
cofactors accounts in part for persistent ERK activation in oxidatively stressed neurons, 
overexpression of these phosphatases could overcome this inhibition and reduce ERK 
phosphorylation.  Although PP2A exists as a multimeric complex in vivo, expression of the 
catalytic subunit alone (i.e. C subunit) can be sufficient for activity (Chung and Brautigan, 1999).  
However, manipulation of PP2A activity in vivo upon catalytic subunit overexpression is 
complicated by the auto-inactivation of PP2A activity that results from C subunit overexpression 
(Chung and Brautigan, 1999; Baharians and Schonthal, 1998).  Futhermore, PP2A has a wide 
range of substrates other than ERK1/2, making it difficult to ascribe biological effects of PP2A 
activity manipulation to effects on a particular substrate (i.e. ERK1/2).  We therefore decided to 
assess the effects of MKP3 overexpression on glutamate toxicity in HT22 cells.  MKP3 is a dual-
specificity phosphatase with a high degree of selectivity toward ERK1/2 that is predominantly 
localized in the cytoplasm (Muda et al., 1996).  The MKP3 point mutant, MKP3 C293S, was 
also tested, because it acts as a dominant negative to block dephosphorylation of ERK by 
endogenous MKP3 as well as to prevent the translocation of phosphorylated ERK to the nucleus 
(Brunet et al., 1999).   
 As expected from previous analyses of MKP3 compartmentalization, MKP3 WT and 
MKP3 C293S are clearly localized in the cytoplasm of transfected HT22 cells (Figures 12B-D).  
In HT22 cells that overexpress transfected MKP3 WT, phospho-ERK levels were dramatically 
reduced (Figure 12A).  The high degree of transfection efficiency that we obtain with the HT22 
cells (i.e., ~80% or higher) allowed for such significant reductions of ERK phosphorylation to be 
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 detected in extracts prepared from the total pool of cells.  Overexpression of the MKP3 C293S 
mutant in the HT22 actually led to an enhancement of ERK phosphorylation which may be 
explained by the dominant negative effect of this mutant on basal MKP3 activity.  Given the 
ability of MKP3 overexpression to affect ERK phosphorylation, we examined their effects on 
glutamate induced oxidative toxicity, which we have shown previously to be ERK-dependent 
(Stanciu et al., 2000; Levinthal and DeFranco, 2004).  In agreement with earlier studies from our 
group, glutamate treatment increased phospho-ERK levels in HT22 cells transfected with an 
empty plasmid (Figure 12A, lanes 1 and 4).  As observed in untreated HT22 cells, 
overexpression of MKP3 dramatically reduced ERK phosphorylation levels in oxidatively 
stressed cultures (Figure 12A, lanes 2 and 5).  Furthermore, MKP3 C293S overexpression was as 
effective as in untreated cultures in increasing phospho-ERK to levels even higher than those 
attained with glutamate treatment alone (Figure 12A, lanes 3 and 6).  Thus, MKP3 
overexpression can be used to manipulate ERK phosphorylation in HT22 cells either under basal 
or oxidative stress conditions.     
 MKP3 C293S acts not only as a dominant negative to sequester ERK away from 
endogenous MKP3, but restricts ERK to the cytoplasm via its selective, high-affinity interaction 
with ERK via its N-terminal domain (Brunet et al., 1999; Tanoue and Nishida, 2003).  As we 
have previously proposed a role for nuclear-localized ERK in glutamate-induced oxidative 
toxicity (Stanciu and DeFranco, 2002), we sought to establish a sensitive, functional test for 
detecting active ERK in the nuclei of MKP3 transfected cells.  Therefore, HT22 cells were 
transfected with MKP3 expression plasmids along with an expression vector for an Elk-1/GAL4 
DBD fusion protein and a luciferase reporter gene under the control of a promoter containing 5 
tandem GAL4 DNA binding sites.  Given that Elk-1 is an established nuclear target of ERK, 
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 enhanced transactivation activity resulting from its phosphorylation by nuclear localized ERK is 
easily monitored through the activity of the luciferase reporter in this system.   
 As confirmation of the sensitivity of this system to the presence of activated ERK in the 
nucleus, luciferase activity was induced nearly two-fold upon glutamate treatment of HT22 cells 
transfected with an empty vector (Figure 12E). Treatment with the MEK inhibitor, U0126, 
blocked the glutamate-induced increase in luciferase activity.  As shown in Figure 12E, MKP3 
WT overexpression reduced luciferase expression below baseline in both untreated and 
glutamate-treated cells, as would be expected from the dramatic reduction in ERK 
phosphorylation (see Figure 12A).  Interestingly, MKP3 C293S overexpression, which led to a 
significant increase in total ERK phosphorylation, led to reduction in luciferase activity in both 
untreated and glutamate-treated cells (Figure 12E).  This result again confirms the sensitivity of 
the system to detect the activity of phosphorylated ERK within the nucleus and establishes the 
ability of MKP3 C293S to restrict nuclear translocation of active ERK in a neuronal cell line, 
consistent with previous work in fibroblast cell lines (Brunet et al., 1999).  Collectively, these 
data show that glutamate-induced oxidative toxicity in HT22 cells is indeed accompanied by a 
functional increase in ERK signaling in the nucleus.   
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Figure 12 Overexpression of MKP3 WT and MKP3 C293S significantly alter ERK 
phosphorylation and translocation in HT22 Cells.  HT22 cells transfected with either empty 
plasmid (pSG5), MKP3 WT, or MKP3 C293S were left untreated or treated with 5 mM 
glutamate for 7.5 hours, and whole cell lysates were prepared.  Western blots from these cells 
demonstrate glutamate-dependent ERK activation in empty vector transfected cells, while MKP3 
WT abrogated, and MKP3 C293S markedly accentuated, ERK activation independently of 
glutamate treatment (A).   Immunocytochemistry against the myc epitope of the transfected myc-
tagged MKP3WT and MKP3 C293S demonstrate a lack of staining in empty plasmid  
transfected HT22 cells (B) and a clearly cytoplamsic pattern of staining in cells transfected with 
the MKP3 WT (C) and MKP3 C293S (D) expression plasmids.  HT22 cells were transfected 
with an Elk-1/GAL4 fusion expression plasmid, a Luciferase reporter plasmid, a Renilla 
expression plasmid, and either an empty plasmid, or either MKP3 WT or MKP3 C293S 
expression plasmids.  Glutamate treated, empty plasmids transfected cells demonstrated a 
significant increase in luciferase expression, whereas both MKP3 WT or MKP3 C293S as well 
as U0126 abrogated this increase (E).  * = p < 0.001 compared to pSG5 control; # = p <0.05 
compared to pSG5 control. 
 
 
 
 
 
 
89 
 5.4.5. Overexpression of MKP3 WT and MKP3 C293S Protects both HT22 Cells and 
Primary Immature Cortical Neurons from Glutamate-Inducted Oxidative Toxicity    
 
Given that MKP3 WT and MKP3 C293S overexpression was effective in manipulating 
both ERK activation and translocation, we sought to determine their impact on glutamate-
induced oxidative-toxicity in both HT22 and primary immature cortical cell cultures.  A single-
cell, toxicity assay was devised that relied on the dual transfection of a mitochondrial-targeted 
eYFP expression plasmid (mt-eYFP) along with either an empty plasmid (pSG5), or either 
MKP3 WT or MKP3 C293S expression plasmids.  After 6-7 hours of glutamate treatment, HT22 
cells with a compromised plasma membrane become permeable to the PI, a DNA dye.  Toxicity 
can be assessed in transfected HT22 cells by determining the percentage of dually-labelled, 
eYFP+/PI+ cells in untreated and glutamate-treated groups.  As can be seen in Figure 13A, 
following transfection with the pSG5 empty plasmid, a significant proportion of HT22 cells were 
dually-labelled upon glutamate treatment.  Co-transfection with either MKP3 WT (Figure 13B) 
or MKP3 C293S (Figure 13C) significantly blocked oxidative toxicity as reflected by a decrease 
in the percentage of dually-labelled cells compared to cultures transfected with empty vector.  
These results are quantified and summarized in Figure 13D.   
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91 
  
 
 
 
 
 
 
 
  
pS
G5
 
pS
G5
+
0
50
75
100
%
 C
el
l D
ea
th
D 
* 
25
 
 
 
 
 
 
Figure 13 Overexpression
glutamate-induced oxidative t
eYFP expression plasmid and
C293S expression plasmids.  T
positive cells within the trans
Photomicrographs of untreate
C293S (C) transfected HT22 
from at least three independen
control. 
 
 
 
 
 
  Gl
u
MK
P3
 W
T
MK
P3
 W
T+
Gl
u
MK
P3
 C
/S
MK
P3
 C
/S+
Gl
u
 of both MKP3 WT and MKP C293S protects HT22 cells from 
oxicity.  HT22 were co-tranfected with a mitochondrial-targeted 
 either an empty plasmid (pSG5), or either MKP3 WT or MKP3 
oxicity was measured as the percentage of propidium iodide (PI) 
fected population in untreated and 5 mM glutamate-treated cells.  
d and treated empty plasmid (A), MKP3 WT (B), and MKP3 
cells are shown.  A summary of counts from three random fields 
t transfections is shown (D).  * = p < 0.01 when compared to pSG5 
92 
  This finding was extended to primary immature cortical neuronal cultures.  These 
cultures were transfected with both the mt-eYFP marker and either pSG5, MKP3 WT, or MKP3 
C293S expression plasmids.  We confirmed that the mt-eYFP transfection marker was localized 
in neurons by immunocytochemical staining of transfected cultures with an antibody to the 
neuronal marker NeuN (data not shown).  Cultures were treated with glutamate, and PI-uptake in 
transfected cells was determined 18-20 hours later (at a time in which cells become PI labeled, 
but before a significant portion have detached from the culture dish).  An example of a dually-
labelled cell in glutamate-treated cultures transfected with empty vector is seen in Figure 14A.  
However, in cultures transfected with MKP3 WT (Figure 14B) or MKP3 C293S (Figure 14C), 
transfected cells were significantly spared from glutamate-induced oxidative toxicity as reflected 
by a reduced proportion of dually-labelled cells within the transfected population.  These results 
are quantified and summarized in Figure 14D. 
 The results of the transfection experiments in HT22 cells and primary immature cortical 
neurons confirm that ERK activation is necessary for cell death during glutamate-induced 
oxidative toxicity.  Furthermore, the fact that MKP3 C293S significantly protected both HT22 
cells and primary neurons from cell death implies that activation of ERK1/2 alone is not 
sufficient to induce toxicity in response to glutathione depletion.  Active ERK1/2 must be 
capable of translocating to the nucleus in order to trigger cell death in oxidatively stressed 
neurons.    
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e 14 Overexpression of both MKP3 WT and MKP C293S protects primary immature 
l HT22 cells from glutamate-induced oxidative toxicity.  Primary immature cortical cells 
co-transfected with a mitochondrial-targeted eYFP expression plasmid and either empty 
id (pSG5), MKP3 WT, or MKP3 C293S expression plasmid.  Toxicity was measured as 
rcentage of propidium iodide (PI) positive cells within the transfected population in 
ted and 5 mM glutamate treated cells.  Photomicrographs of untreated and treated empty 
id (A), MKP3 WT (B), and MKP3 C293S (C) transfected HT22 cells are shown.  A 
ary of counts from three random fields from at least three independent transfections is 
 (D).  * = p < 0.001 when compared to untreated pSG5. 
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 5.5. DISCUSSION  
 
 Although thiol-oxidation and inactivation of phosphatases has been shown in numerous 
cellular systems to be a feature of normal cellular signaling events (Meng et al., 2002) and to 
occur during ROS accumulation in neuronal cell lines (O'Loghlen et al., 2003), the role of this 
mechanism in oxidative stress-induced neurotoxicity has not been assessed previously.  In this 
report, ERK-directed phosphatase activity was found to be specifically inhibited during times of 
oxidative stress, while phosphatases regulating other MAPKs, such as JNK1, were not affected.  
This inhibition of ERK-directed phosphatase activity is coincident with the temporal pattern of 
ERK activation that occurs during glutamate-induced oxidative toxicity – only at times in which 
inhibition of ERK-directed phosphatase activity is detected do we observe a concurrent increase 
in phosphorylated ERK1/2.  These findings of substrate specificity and temporal congruence 
strongly indicate that oxidative inhibition of ERK-directed phosphatase activity is a mechanism 
that drives ERK activation and propels neurons toward a cell-death pathway.  Based upon 
inhibitor studies, PP2A and vanadate-sensitive phosphatases appear to be the likely phosphatases 
that mediate this effect.     
 Many studies have demonstrated p38 and JNK activation during oxidative stress in 
numerous cell types, including primary cortical neuronal cultures (McLaughlin et al., 2001; 
Crossthwaite et al., 2002).  We do not observe JNK or p38 activation in either HT22 cells or 
primary cortical neuronal cultures during glutatamte-induced oxidative toxicity.  A potential 
reason for this disparity could be attributed to differences in the complement of MAPK-directed 
phosphatases that are expressed in various cellular systems or to the specificity to which certain 
phosphatases, even within one cell type, may be inhibited by oxidative stress.  We have shown 
that JNK-directed phosphatases are not inhibited by oxidative stress in primary cortical cultures, 
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 and that this correlates with the lack of increased JNK phosphorylation during oxidative stress.  
Thus JNK-directed MAPK phosphatases, such as M3/6, may not be as sensitive to oxidation as 
ERK-directed phosphatases, such as MKP3 or STEP.  Further work clearly needs to be done to 
determine the differential sensitivities of various phosphatases to oxidation, as this has a direct 
implication for potential mechanisms of oxidative signaling.         
 A number of mechanisms could account for oxidation-dependent phosphatase inhibition.  
Protein-tyrosine phosphatases exhibit sensitivity toward oxidation of the catalytic cysteine (Sohn 
and Rudolph, 2003), and inactivation can occur by both reversible and irreversible mechanisms.  
Because both tyrosine-directed and dual-specificity phosphatases share a canonical HC(X)5R 
motif in their active sites, it is likely that both classes undergo similar mechanisms of inhibition.  
Conversion of the active-site cysteine to a metastable sulfenic acid (Cys-SOH) (Meng et al., 
2002) or the involvement of this cysteine in the formation of an intramolecular disulfide bond 
(Sohn and Rudolf, 2003) are both reversible with thiol-reducing agents.  A novel mechanism of 
reversible oxidative inhibition of PTP-1B was recently identified that involves the formation of a 
sulphenyl-amide stable intermediate resistant to further oxidation (van Montfort et al., 2003; 
Salmeen et al., 2003).  However, the extent to which this mechanism operates in other 
phosphatases is currently unknown.  Progression of these reversible states to sulfinic (Cys-SO2H) 
or sulfonic (Cys-SO3H) acid forms leads to irreversible phosphatase inhibition.  Since we 
observe total reversibility of oxidative phosphatase inhibition with the thiol-reductant DTT, 
oxidation of ERK-directed phosphatases to sulfinic and sulfonic forms are unlikely to occur in 
the oxidatively stressed neuronal cultures that we analyzed.  Furthermore, the fact that activity is 
recoverable with DTT rules out the possibility that decreased ERK-directed phosphatase activity 
during oxidative stress reflects decreased phosphatase expression (Vasudevan et al., 2004) or 
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 increased phosphatase degradation (Lin et al., 2003).  The restoration of ERK-directed 
phosphatase activity with DTT is likely to represent a direct effect on the phosphatases 
themselves.  However, it is formally possible that DTT is reversing the thiol-oxidation of 
cofactors necessary for ERK-directed phosphatase function.  The identification of both the sites 
of oxidation and the mechanism of inhibition of specific ERK-directed phosphatases during 
oxidative stress will be the subject of future studies.  
 Although redox modification of cysteine residues plays an important role in protein 
phosphatase inhibition, other mechanisms are possible, such as nitrosylation or glutathionylation 
of residues within the protein, or oxidation of Fe-Zn metal clusters that are critical for the 
function of Ser/Thr-directed phosphatases.  In fact, oxidative-inhibition of Ser/Thr-directed 
phosphatases is not well understood and may reflect effects on oxidant-sensitive regulatory 
subunits.  Nonetheless, oxidative-stress induced inhibition of phosphatases is likely to represent a 
common mechanistic thread that drives cellular signaling events during neuronal cell death in a 
diverse range of conditions, such as in stroke, Alzheimer's Disease, or Parkinson's Disease.  
Indeed, PP2A activity has been found to be reduced in the cortices of Alzheimer's patients as 
compared to control patients (Gong et al., 1995), and ERK has been found to be activated in 
these tissues (Pei et al., 2002).  Tau is a well-described ERK1/2 target (Pei et al., 2003), and the 
hyperphosphorylation of tau protein and the development of neurofibrillary tangles in 
Alzheimer's Disease pathology could reflect aberrant ERK1/2 activity (Pei et al., 2003).  
Interestingly, mice expressing a dominant negative form of PP2A in neurons display features of 
Alzheimer's pathology (Kins et al., 2003).  Thus, oxidative stress-mediated PP2A inhibition in 
Alzheimer's disease may account for enhanced ERK1/2 activity and subsequent tau 
hyperphosphorylation and neurofibrillary tangle formation.         
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  Because the endogenous pool of PP2A and vanadate-sensitive phosphatases is inactivated 
during oxidative toxicity in primary neurons, we sought to overexpress one of these phosphatases 
to attempt to overcome this inhibition and impact ERK activation.  The choice of MKP3 as a tool 
to manipulate ERK activity in our system was made for several reasons.  MKP3 is localized in 
the cytoplasm and physically interacts with ERK1/2 at a kinase-interacting motif (KIM) domain 
in its N-terminus in a highly specific manner.  Brunet et al. elegantly showed that the 
overexpression of MKP3 WT could extinguish ERK1/2 signaling, whereas overexpression of the 
catalytic mutant, MKP3 C293S, could abolish ERK1/2 signaling specifically in the nucleus by 
acting to trap activated ERK1/2 in the cytoplasm via its physical interaction with MKP3 (Brunet 
et al., 1999).   
 Shuttling of phospho-ERK into and out of the nucleus is a dynamic process, and standard, 
static immunocytochemical fluorescence imaging techniques may not be sufficient to detect 
small shifts in the equilibrium of the subcellular distribution of phospho-ERK.  However, these 
small changes in the distribution of phospho-ERK could have important biological 
consequences.  We therefore employed a sensitive, quantifiable, and functional assay to assess 
nuclear residency of active ERK during glutamate-induced oxidative toxicity.  In this assay, 
luciferase expression was controlled by the activation of an Elk-1-GAL4 fusion by active-ERK 
in the nucleus.  We found that Elk-1-Gal4 directed luciferase expression increases with oxidative 
stress in HT22 cells and that both MKP3 WT and MKP3 C293S block this increase.  Thus, 
glutamate-induced oxidative stress leads to an increase in active ERK function within the 
nucleus.  Even though it is predominantly localized within the cytoplasm, overexpressed wild-
type MKP3 can deplete the total cellular pool of active ERK most likely by acting upon 
dynamically shuttling ERK during its transit through the cytoplasm.  Overexpression of the 
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 MKP3 C293S mutant exerts a dominant negative effect to block endogenous MKP3 and elevate 
ERK phosphorylation.  Elevated phospho-ERK in this case is not accessible to the Elk-Gal4 
fusion in the nucleus due to its sequestration with the cytoplasm by the MKP3 C293S mutant 
(Brunet et al., 1999). 
 Despite the likelihood that multiple phosphatases from a diversity of classes are 
responsible for the regulation of ERK phosphorylation, MKP3 overexpression was sufficient to 
manipulate ERK activity in oxidatively stressed neurons and revealed consequences of ERK 
activation and localization on toxicity.  Thus, inhibition of ERK activation was brought about by 
MKP3 overexpression and led to significant protection from oxidative toxicity in both HT22 
cells and immature cortical neuronal cultures.  Obviously, the overexpression was sufficient to 
overcome the oxidation-induced inhibition of endogenous ERK-directed phosphatases in the 
primary neurons.  Elevation of ERK activation brought about by MKP3 C293S overexpression 
also was protective in both contexts presumably based upon the sequestering of active ERK in 
the cytoplasm.  Thus, we hypothesize that ERK-directed toxicity in oxidatively stressed neurons 
requires some translocation of active ERK to the nucleus.  We are currently in pursuit of specific 
targets of ERK that may be mobilized, even in response to the transient nuclear accumulation of 
active ERK, to trigger neuronal cell death in response to oxidative stress.    
 ERK activation occurs downstream of ROS production in primary immature cortical 
cultures undergoing glutamate-induced oxidative toxicity.  We have previously monitored ROS 
in primary immature cortical cultures, and ERK inhibition via U0126 administration did not alter 
the rate or extent of ROS production in these cells during glutamate-induced oxidative toxicity 
(Levinthal and DeFranco, 2004).  We observe that ERK-directed phosphatases are still inhibited 
in glutamate-induced oxidative toxicity in the presence of U0126 (data not shown), a treatment 
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 that protects these cultures from cell death.  This indicates that the ERK-directed phosphatase 
inhibition is not sufficient for toxicity in of itself, but must act through specific activation of 
ERK.  Furthermore, it also implies that there is a requirement for MEK activity to provide a 
forward drive for ERK activation during oxidative stress (Levinthal and DeFranco, 2004) in 
primary immature cortical cultures.   
 The results reported here represent the first demonstration of the critical toxic role of 
ERK1/2 activity in the nucleus using a molecular approach rather than relying upon inhibitor 
studies, which can not resolve the distinction between ERK1/2 activation as a whole versus the 
translocation of active ERK1/2.  Thus, the spatio-temporal pattern of ERK activation during 
glutamate-induced oxidative toxicity is critical for determining the cellular response to this 
insult.  Nuclear targets of ERK must be mobilized to bring about oxidative toxicity in neurons.  
We also have implicated an intriguing mechanism by which oxidative stress may be coupled to 
ERK activation.  Specific oxidation of ERK-directed phosphatases during glutamate-induced 
oxidative toxicity could drive ERK activation, and nuclear accumulation, leading to neuronal cell 
death.  We are now fully engaged in determining the specific phosphatases that are involved in 
mediating this effect and the mechanism by which they are inhibited by oxidative stress.       
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 6. CONCLUDING REMARKS 
 
 The recruitment and activation of cellular signaling pathways were once thought to be 
primarily involved in the integration and transduction of signals emanating from hormones, 
neurotransmitters, growth factors, cell-cell and cell-extracellular matrix contact, among 
numerous other factors, that impinged upon the cell from the surrounding milieu.  Recently, 
cellular stressors such as irradiation, ischemia, heat shock, and oxidative stress have been shown 
to activate cell signaling pathways in the absence of clearly defined ligand-receptor interactions.  
The mechanisms by which cellular stressors lead to the activation of signaling events and 
eventual stress responses are just beginning to be identified, but clearly these responses are 
highly individualized across specific cell types and for specific stressors.  The data presented 
here provide insight into the mechanisms by which a specific cellular signaling pathway, the 
ERK-MAPK pathway, is recruited during oxidative stress-induced neuronal cell death.  This 
ERK activation was shown to be dependent upon the tonic activity of the PI3K-Akt pathway and 
subsequent PI3K-dependent MEK activation.  Furthermore, the persistent ERK activation that 
leads to cellular toxicity can be driven by the oxidation-dependent inactivation of ERK-
phosphatases.  The balance of activating kinase activity and inactivating phosphatase activity 
dynamically regulates ERK-dependent signaling and is a major determinant of neuronal cell 
responses to oxidative stress.  Thus, the reduction of ERK signaling by the administration of 
inhibitors (Chapter 1) and the overexpression of ERK-specific phosphatases (Chapter 2) can 
overcome glutamate-induced oxidative toxicity in both HT22 cells and in primary immature 
cortical cultures.  These results clearly place ERK activation as a necessary event that leads to 
neuronal cell death during oxidative stress.  A summary of the important cellular events during 
glutamate-induced oxidative toxicity is shown in the model diagram below (Figure 15).   
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Figure 15 Schematic summary diagram. 
 
 
6.1. PI3K as a Mediator of Neuronal Cell Death 
 
 ERK activation during glutamate-induced oxidative toxicity in primary cortical cultures 
is PI3K-dependent during its initial phase, but not for the delayed, prolonged ERK activation that 
occurs at times of increasing oxidative stress.  Cross-talk between the PI3K-Akt and ERK 
signaling pathways has been demonstrated in many studies, but typically "cross-talk" implies a 
direct action of one pathway on another (i.e., via direct phosphorylation).  Because the loss of 
PI3K-Akt signaling several hours preceding, but not during, the accumulation of ROS leads to 
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 the abrogation of ERK signaling, it is unlikely that PI3K activity is directly involved in the 
activation of ERK.  Interestingly, we did not observe phosphorylation of Akt, the primary 
downstream target of PI3K, upon glutamate administration, and thus the link between PI3K 
activity and ERK activation is not likely via an Akt-dependent mechanism.  A potential link 
between these two signaling pathways could be via calcium channels that are under the tonic 
control of PI3K.  As discussed in Chapter 1, several calcium channels in both neurons and non-
neuronal cells have been identified as PI3K-sensitive and are relatively impermeable to calcium 
flux in the presence of the PI3K inhibitors LY294002 or wortmannin.  Because calcium influx 
into the cell via plasma membrane Ca2+ channels is an important feature of glutamate-induced 
oxidative toxicity (Tan et al., 1998), it is possible that PI3K inhibition renders these channels 
inactive, breaking the mechanistic link between oxidative stress, calcium influx, MEK activation, 
and eventual ERK activation.  Although MEK inhibitors have been shown to block rises in 
intracellular calcium levels in HT22 exposed to glutamate-induced oxidative toxicity (implying 
that MEK functions upstream of calcium entry in these cells), the relationship between calcium  
and ERK in primary neurons has not been investigated.  Future studies will be needed to 
determine whether calcium entry in primary immature cortical neurons exposed to glutamate-
induced oxidative toxicity (Li et al., 1997) functions upstream of MEK and subsequent ERK 
activation, the nature of those calcium channels (i.e. L-type versus N-type), and the PI3K-
senstivity of those calcium channels.      
 The identification of PI3K as a positive contributer to oxidative stress-induced neuronal 
cell death is quite surprising given that this pathway has been universally ascribed a role in cell 
survival across a vast array of cell types and cellular stressors.  The data described here are the 
first to demonstrate that PI3K activity is necessary for some forms of cell death.  Interestingly, 
104 
 since the publication of the material in Chapter 1 (Levinthal and DeFranco, 2004), two research 
groups have identified a similar mechanism of PI3K dependent cell death.  One study has made 
use of a model of interferon (IFN)-induced cell death in multiple myeloma cells.  In this case, 
although IFN did not activate Akt above basal levels, PI3K inhibition with LY294002 protected 
against toxicity by preventing the recruitment and activation of caspases (Thyrell et al., 2004).  
Furthermore, NO-induced apoptosis was found to be PI3K-dependent in cultured mouse 
astrocytes (Yung et al., 2004).  Additionally, this study revealed the lack of Akt activation during 
toxicity, and LY294002 was not toxic to astrocytes when administered alone (Yung et al., 2004).  
All of these results are completely consistent with my findings in glutamate-treated primary 
immature cortical cells and underscore the potential role for PI3K to act independently of Akt to 
contribute to a cell death process.         
 
6.2. Oxidation Dependent Inhibition of ERK-directed Phosphatases 
 
 The identification of mechanisms by which oxidative stress conditions are linked to 
cellular signaling events has received an increasing amount of attention and is truly an area of 
intense investigation.  As mentioned above, oxidative stress is a cellular condition that appears to 
lack the specificity of traditionally described ligand-receptor or protein-protein interactions that 
initiate signaling events.  However, oxidative stress conditions do specifically activate subsets of 
signaling pathways, and this phenomenon is now referred to as oxidative signaling given that 
cellular oxidants are now becoming viewed as bonefide second messengers.  The identification 
of several protein phosphatases that are uniquely sensitive to reversible oxidative inhibition has 
led to a conceptual model in which protein phosphatases act as redox sensors for the cell and 
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 function proximally to initiate signaling.  The oxidation of specific phosphatases could be a 
generalized mechanism by which oxidative stress is linked to the activation of specific signaling 
cascades. The development of strategies that disrupt these mechanisms during pathological 
conditions are likely to lead to novel therapeutic approaches to several disorders that depend 
upon the production and accumulation of ROS and in which aberrant signaling events have been 
shown to occur, such as ischemia/reperfusion injury following a stroke, Parkinson's Disease, 
Alzheimer's Disease, and Amyotrophic Lateral Sclerosis.      
 Most of the data supporting a role for oxidation-dependent phosphatase inhibition has 
come from studies of growth factor ligand-receptor interactions in fibroblast cell lines.  In these 
models, the recruitment and activation of signaling complexes at the plasma membrane in 
response to ligand binding is accompanied by the localized production of ROS that inactivate 
specific phosphatases.  These inactivated phosphatases, such as SHP-2, are necessary for the 
amplification of signaling downstream of activated receptors (e.g., PDGF receptors) and 
treatment with antioxidants can abrogate signaling (Meng et al., 2002).  Although oxidative 
conditions do not universally inhibit all phosphatases, the mechanisms governing the oxidative 
sensitivity of one phosphatase versus another are currently unknown.  Furthermore, the extent to 
which oxidation-dependent inhibition of phosphatases operates as a generalized mechanism in 
growth factor signaling in all cell types is being actively pursued by several research groups.  
Localized production of ROS may function in normal signaling events as important second 
messengers, and this discovery is likely to revolutionize the field of cellular signaling much in 
the same way that it was changed following the identification of nitric oxide and carbon 
monoxide as gaseous signaling molecules.  The development of new tools to measure oxidation-
dependent modifications on target proteins is likely to drive an explosion in future research.  A 
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 recent proof-of-principle study used antibodies raised against the oxidized form of the active site 
cysteine residue within the phosphatase receptor-like PTPα (RPTP).  Oxidation-dependent 
modifications on this phosphatase and others, including SHP-2, were detected during exposure to 
hydrogen peroxide and during normal PDGF signaling (Persson et al., 2004).  This approach is 
quite exciting, as the future of this field of research is likely to employ these reagents much in 
the same way phospho-specific antibodies are used now to detect post-translational 
phosphorylation modifications on target proteins. 
     The data presented in Chapter 2 are the first to implicate oxidation-dependent 
phosphatase inhibition as an important event during the unfolding of oxidative-stress dependent 
neuronal cell death.  Several groups have identified ROS-dependent MAPK member activation 
in both neuronal and non-neuronal cells, but the role of potentially reversible, inactivated 
phosphatases acting as the causal link between ROS and MAPK activation had not been 
explored.  I have found that ERK-directed phosphatase activity is inhibited by oxidation during 
times of oxidative stress that correlate with the upregulation of ERK activity.  This occurs 
specifically for the ERK MAPK pathway, as JNK-directed phosphatase activity is not inhibited 
and JNK activation is not observed.  Furthermore, inhibition of ERK-directed phosphatase 
activity was completely reversible by thiol-reducing agents such as DTT.  Although this is clear 
evidence that oxidation-dependent inhibition of ERK-phosphatase activity occurs through the 
oxidation of cysteine thiols, it is not clear whether this represents a direct effect on the 
phosphatases themselves, or whether thiol-oxidation alters one or more intermediate phosphatase 
regulatory proteins.  This issue may be more relevant for serine/threonine-directed protein 
phosphatases, which in many cases interact with regulatory subunits in vivo, than for the 
PTPs/DSPs, which do not typically interact with subunits other than their specific protein targets.  
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 Further studies monitoring the activity of isolated phosphatases from oxidatively stressed cells 
(i.e., via immunoprecipitation and phosphatase activity assays) will be necessary to determine 
the direct versus indirect nature of oxidation-dependent phosphatase inhibition.   
 I used inhibitors to determine the nature of the oxidation-sensitive phosphatases in 
primary immature cortical cultures and found that the main component of ERK-directed 
phosphatase activity was inhibited by okadaic acid, while a smaller component was inhibited by 
orthovanadate.  This implicates PP2A as a primary oxidation-sensitive ERK-directed 
phosphatase in cultured neurons, while the remaining phosphatases are likely PTPs or DSPs.  
However, as mentioned above, future studies will require direct measurements of PP2A activity 
to prove that this phosphatase becomes directly inhibited during oxidative stress and that this 
inhibition can be reversed by thiol-reducing agents.  These studies can be accomplished by 
immunoprecipitating PP2A and determining phosphatase activity directly by measuring the 
extent of cleavage of well-characterized, phosphorylated substrates such as pNPP or Malachite 
Green.  Although orthovanadate lacks resolution as an inhibitor, there are several vanadate-
sensitive attractive candidate PTPs/DSPs that operate within neurons.  STEP, MKP3, and MKP1, 
are expressed in neurons and are active against phosphorylated ERK.  The oxidation-dependent 
inhibition of these targets will need to be tested, as they could also contribute to persistent ERK 
activation during oxidative stress. 
 While glutamate-induced oxidative toxicity in primary immature cortical cultures is a 
convenient model system for the study of oxidative stress-induced neurodegeneration, the study 
of animal models of oxidative stress-dependent neuronal toxicity may be more directly relevant 
to human pathology.  The middle cerebral artery occlusion (MCAO)-reperfusion model in 
rodents is an excellent paradigm that models a stroke in vivo, and a significant proportion of 
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 strokes in humans develop subsequent to transient blockages in the MCA or its branches.  In the 
MCAO model, the middle cerebral artery, which in rats supplies oxygen and nutrients to most of 
the cortex, hippocampus, and striatum, is blocked either from within the vessel lumen or by 
constriction from outside of the vessel, and neuronal damage is restricted to the ipsilateral side.  
Other models of more global neuronal damage, such as the four-vessel occlusion model, are 
more relevant for modeling the brain damage that occurs in conditions where oxygenated blood 
flow is impaired systemically, such as during a heart attack.  Several aspects of the MCAO focal 
ischemia-reperfusion model have been characterized, including the regional pattern and time 
course of neuronal degeneration, histological and biochemical markers of necrosis and apoptosis, 
as well as the dependence upon the activation of specific signaling pathways.  After a brief 
decrease immediately after MCAO, ROS steadily accumulate above baseline over long occlusive 
periods (i.e., 3 hours or more) and show a robust increase in formation and accumulation in the 
minutes following reperfusion (Peters et al., 1998).  Whereas the initial accumulation of ROS 
during ischemia has been associated with mitochondrial dysfunction, the cellular source of the 
burst of ROS during reperfusion is not well characterized (Becker, 2004).  However, because the 
production and accumulation of ROS is a necessary feature of neurodegeneration in the MCAO 
model and ERK is specifically activated and associated with neuronal cell death in this context 
(McCulloch and Dewar, 2001; Noshita et al., 2002), oxidation-dependent inhibition of ERK-
directed phosphatases could drive ERK activation and neuronal toxicity during 
MCAO/reperfusion.  Indeed, transgenic mice that overexpress Cu/Zn SOD1 show resistance to 
MCAO-induced neurodegeneration specifically by preventing the activation of ERK via 
decreases in ROS production (Noshita et al., 2002).  Future studies in our group will investigate 
the potential role of oxidation dependent ERK-phosphatase inhibition in the activation of ERK in 
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 several disease models, including the MCAO model, that have been shown to involve oxidative 
toxicity. These studies may suggest novel approaches to therapies that target the potential 
maladaptive interaction of phosphatases and ERK during oxidative stress. 
 
6.3. Subcellular Localization of ERK during Oxidative stress 
  
 In Chapter 2, I conclusively demonstrate that ERK translocation to the nucleus is 
necessary for neuronal oxidative toxicity in both HT22 cells and primary immature cortical 
cultures.  I used two important molecular tools to manipulate ERK in transfected cells.  
Overexpression of the cytosolic, ERK-specific phosphatase MKP3 and a catalytically inactive 
mutant MKP3 C293S can impact ERK activation and translocation, respectively.  These two 
forms of MKP3 were first used in an influential and elegant study of ERK nuclear translocation 
and cell cycle dysregulation in fibroblasts (Brunet et al., 1999), but they have not been 
previously used in models of neuronal toxicity.  This molecular approach is superior to the 
traditional use of chemical inhibitors because these inhibitors may impact other pathways and, 
more importantly, they fail to dissociate ERK activation from ERK translocation to the nucleus.  
MKP3 is a specific ERK phosphatase that resides in the cytoplasm.  MKP3 C293S 
overexpression leads to increased levels of phosphorylated ERK, yet prevents its translocation to 
the nucleus by physically binding to active ERK in the cytoplasm.  The use of MKP3 WT and 
MKP3 C293S will likely provide insights into the necessity of ERK activity and nuclear 
translocation both in normal neuronal functioning and in various models of neuronal toxicity.   
Furthermore, MKP3 WT and MKP3 C293S could be useful tools to resolve long-standing 
controversies surrounding ERK localization in neurons.  For example, although current 
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 immunohistochemical or cellular fractionation techniques can be spatially precise in identifying 
ERK localization at a given moment in time, they are hampered by an inability to monitor 
complex events that involve rapid shuttling between cellular compartments over time.  Thus, 
studies using these techniques cannot give an accurate representation of the nuclear residency 
time for ERK and other proteins that rapidly shuttle between the nucleus and the cytoplasm, nor 
can they definitively demonstrate the necessity of ERK translocation to the nucleus in the studied 
paradigm.  Several studies have implicated the nuclear localization of ERK as a requisite event in 
the development of long term potentiation at hipppocampal synapses.  For example, cAMP-
mediated long term potentiation is associated with nuclear translocation of phospho-ERK in 
hippocampal slice cultures (Patterson et al., 2001), and ERK-dependent CREB phosphorylation 
(Impey et al., 1998; Davis et al., 2000).  However, the absolute necessity of nuclear localized 
ERK for the development of long lasting LTP is not known and has been difficult to establish 
because MEK inhibitors, which do disrupt LTP formation (Davis et al., 2000), globally suppress 
ERK phosphorylation in all cellular compartments.  Thus, the expression of MKP3 C293S in 
hippocampal neurons could physically restrict ERK to the cytoplasm and would definitively 
demonstrate the requirement of ERK nuclear translocation in the development of LTP.  
Similarly, ERK translocation during Aβ and Fe-induced neuronal toxicity in primary cortical 
cultures has been implicated as a necessary feature of this mode of neuronal cell death by 
immunocytochemical methods and the application of MEK inhibitors (Kuperstein and Yavin, 
2002).  Such data is only associative, and the expression of MKP3 C293S in these cells would 
again definitely demonstrate the necessity of ERK translocation in Aβ/Fe neuronal toxicity.  The 
use of molecular tools, such as MKP3 WT and MKP3 C293S, to independently manipulate both 
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 the subcellular localization and activity of ERK in neurons is an exciting development that will 
greatly refine and enhance studies that focus on this pathway in neurons and in other cell types.             
 The use of genetically altered mice has been somewhat instructive in examining the 
functioning of ERK isoforms during higher order processes and behaviors.  As described earlier, 
although ERK2 knockout (KO) mice show an embryonically lethal phenotype, some forms of 
learning are enhanced in ERK1 KO mice (Mazzucchelli et al., 2002).  However, these studies 
made use of global knockouts of ERK1 or ERK2, and the interpretation of the results are 
complicated by the same issues that plague most KO studies – the potential compensation for 
function by other pathways, the diffuse nature of the genetic manipulation, and developmental 
effects, among others.  Temporally controlled downregulation of the ERK1/2 pathway in a 
subset of cells could be achieved by placing MKP3 WT under a tetracycline regulatable, tissue 
specific promoter.  However, this system would still rely on alterations in gene expression, and 
tight temporal control would be difficult to achieve.  These issues are significantly resolved by 
the use of high affinity tamoxifen-binding estrogen receptor (ER) mutant fusion proteins.  Many 
enzymes, when physically tethered to ER within a chimeric fusion protein, are inactive in the 
absence of tamoxifen but become responsive in the presence of this drug.  One of the first uses of 
this technology was in the construction of temporally and spatially inducible KO mice in which 
the chimeric CRE-recombinase/ER fusion was expressed under tissue specific promoters, and 
floxed genes containing Lox-P CRE-targeting sites were specifically disrupted in those tissues 
upon tamoxifen treatement (Li et al., 2000). Furthermore, the activity of other enzyme-ER 
chimeras has been shown to be tamoxifen dependent in vivo.  For example, tamoxifen has been 
shown to drive Raf-1-ER fusion protein-dependent MEK and ERK activation in stably-
transfected cell lines (Le Gall et al., 2000).  Placing the expression of other chimeric enzymes 
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 under tissue specific promoters may thus lead to unparalleled temporal and spatial control over 
enzymatic functioning in vivo.   
 Particularly intriguing is the possibility of constructing tamoxifen-inducible ER-MKP3 
WT or ER-MKP3 C293S fusion proteins.  These constructs would add a dimension of temporal 
control such that MKP3 activity or MKP3 C293S action would be unleashed in the presence of 
tamoxifen.  The ability to restrict ERK activity directly or to restrict ERK localization to the 
cytoplasm in a temporally controlled manner would be an impressive tool to probe multiple 
systems.  If these constructs operate as predicted in vitro, then we would expect tamoxifen 
treatment to protect transfected HT22 cells and primary neuronal cultures from oxidative 
toxicity.  If this experimental paradigm were successful in cultured cells, we would proceed to 
engineer transgenic animal expressing each of these constructs under tissue specific promoters, 
such as the calmodulin II (CamII) kinase promoter that specifically targets the neurons of the 
forebrain.  Thus these animals would be sensitive to tamoxifen and would respond by 
downregulating ERK activity or ERK translocation specifically in neurons.  Major studies that 
have relied on MEK inhibitors to determine the ERK-dependence of such important and diverse 
processes as learning and memory and neuronal cell death after ischemia / reperfusion could be 
replicated in these transgenic animals with a specificity never achieved before.     
 In summary, the work presented in this thesis has definitively established that the 
regulation of ERK activation and translocation is a major determinant of cell fate during 
glutamate-induced oxidative toxicity in both HT22 cells and primary immature cortical cultures.  
ERK activation is dependent upon tonic PI3K activity in cortical cultures, and sustained 
activation is likely driven by the oxidation-mediated inhibition of ERK-directed phosphatases.  
Manipulations of ERK activity and nuclear translocation using MKP3 show that it is the 
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 translocation of active ERK to the nucleus, not ERK activation per se, that is necessary for 
toxicity.  Collectively, these data have clarified the role of ERK during glutamate-induced 
oxidative toxicity and have identified a novel mechanism that drives ERK-dependent neuronal 
cell death.  Future studies will be directed toward manipulating active ERK in the nuclear 
compartment by expressing nuclear, ERK-directed phosphatases that can act either to diminish 
ERK activity (i.e., through the WT form of the phosphatase) or lead to sequestration of active 
ERK in the nucleus (i.e., through the catalytically inactive form of the phosphatase).  Good 
candidate phosphatases for manipulating ERK in this manner would be MKP1 and B23.   
 Exploration of the mechanisms governing the redox sensitivity and reversible inactivation 
of phosphatase function is an intriguing new horizon in the field of cellular signaling research.  
Indeed, redox-dependent alterations in protein functioning may be revealed as a ubiquitous 
mechanism by which purposefully and locally produced ROS/RNS act as signaling molecules 
themselves during a host of normal cellular processes.  Thus, thiol-oxidation and other redox 
dependent changes could enter the pantheon of post-translational protein modifications that 
include phosphorylation, glycosylation, and ubiquitination, among numerous others.  The 
identification of oxidation-inactivated phosphatases as uniquely sensitive redox sensors has 
bridged the mechanistic link between ROS production and the activation of specific cellular 
signaling pathways.  It is likely that future studies of disease will reveal this mechanistic link to 
be involved in a host of disorders that involve oxidative stress, and future therapies may target 
this mechanism.   
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